



STS National Database™
Trusted. Transformed. Real-Time.

Intermacs

STS Intermacs

Quarterly Quality Assurance Report (2021 Q2) - All Patients

HOSPX - DEMO SITE REPORT

Implant and event dates: June 23, 2006 to June 30, 2021

09/30/2021

Prepared by:

Intermacs Data Warehouse and Analytics Center
University of Alabama at Birmingham

James K. Kirklin, MD
Craig Collum, MPH
Ryan S. Cantor, PhD
Nick Timkovich, MSHI
Maceo Cleggett
Kathryn Hollifield, BSN RN

**CONFIDENTIAL: This information is only intended for:
HOSPX - DEMO SITE REPORT**

About This Report

The “Cumulative” version of the Quality Assurance report focuses on the complete cohort of patients. This report includes all patients enrolled in Intermacs within the report coverage window.

The “All Patients” version of the report includes all patients enrolled at your center whose first device was implanted within the report coverage window.

Confidential

This report is intended only for STS Intermacs personnel at the hospital named on the cover of this report. Distribution of the report to other personnel within the hospital is left to the discretion of the STS Intermacs site administrator and physician representative. The STS Intermacs data in this report may not be distributed to anyone outside of your hospital. STS Intermacs has a separate mechanism for the creation and distribution of STS Intermacs aggregate data.

Disclaimer

STS Intermacs has attempted to create a high quality report that is a direct result of the data submitted by the STS Intermacs hospitals. However, STS Intermacs makes no warranties or representations, either expressed or implied, about the content of this report. STS Intermacs further disclaims any and all liability whatsoever in any information, material, or content of this report. Any reference in this report to any specific commercial product, service, manufacturer, or company does not constitute its endorsement or recommendation by STS Intermacs or its employees or agents. None of the material, information or content from this report shall serve as or create a contract between Intermacs and any person or entity accessing and using this report. The recipient of this report agrees to abide by the confidentiality laws of the United States, all other applicable federal and state laws, and applicable policies and guidelines of STS Intermacs. Comments involving information perceived as inaccurate, misleading, or inappropriate should be directed to: Maceo Cleggett with the Intermacs Data Warehouse and Analytics Center at INTERMACS-Reports@uabmc.edu.

This quarterly report includes clinical information from 806 patients receiving implants between June 23, 2006 and June 30, 2021 at HOSPX - DEMO SITE REPORT.

Table of Contents

- I. Introduction and Methods**
 - A. Purposes of this Report**
 - B. Source of Data and Limitations**
 - C. Statistical Summaries and Benchmarks for Quality Assurance**
 - D. Registry Compliance**
 - E. Future Reports**
 - F. Report Coverage - Patient Selection**
- II. Statistical Summaries and Benchmarks for Quality Assurance**
 - A. Pre-implant Summaries**
 - Demographics
 - Clinical Characteristics
 - Concerns and Contraindications
 - Hemodynamics
 - Functional Capacity and Quality of Life
 - Additional Interventions
 - B. Implant Summaries**
 - C. Post Implant Summary**
 - Adverse Event Rates
 - Adverse Event Timing
 - Time to First Device Malfunction and/or Thrombus
 - Time to First Infection
 - Time to First Neurological Dysfunction
 - Hospitals Days
 - 30 Day Readmission Rates
 - Functional Capacity
 - Quality of Life
 - D. Post Implant Risk Adjusted Outcomes**
 - E. Post Implant Outcomes**
 - Survival
 - Competing Outcomes
- III. Zone Conditions: Hemolysis, Hypertension, and Right Heart Failure**
 - Hemolysis
 - Hypertension
 - Right Heart Failure
- IV. Registry Compliance**
- V. Glossary**

Topics in **grey** are not part of this report, but will become part of future reports.

I. Introduction and Methods

I.A. Purpose of this Report

As specified by the STS Intermacs Leadership, the primary goals of the registry are:

- Facilitate the refinement of patient selection to maximize outcomes with current and new device options.
- Identify predictors of good outcomes as well as risk factors for adverse events after device implantation.
- Develop consensus best practice guidelines to improve clinical management by reducing short and long term complications of MCSD therapy.
- Guide clinical application and evolution of next generation devices.
- Utilize Registry information to guide improvements in technology, particularly as next generation devices evolve.

Consistent with these goals, we have greatly expanded our site reports to move towards these goals at the hospital and patient level. Specifically, these reports will provide information in the following areas:

- Statistical Summaries and Benchmarks for Quality Assurance
- Patient Level Data
- Registry Compliance
- Data Quality Queries

I.B. Source of Data and Limitations

The data in this report are based on all data entered into the STS Intermacs web-based data application through June 30, 2021. Patient enrollment in STS Intermacs began on June 23, 2006 and retrospective entry of patients with implants after March 1, 2006 was allowed. Your institution may have joined STS Intermacs at a later date and therefore your patient enrollment may have begun at a later date. This report is restricted to your patients who were implanted after your enrollment date and received a primary implant.

STS Intermacs is a registry that strives to meet the data quality standards of a prospective clinical trial. STS Intermacs is an on-going registry and therefore data quality efforts will always have an associated lag time.

As you review the data from your hospital that are contained in this report, you may find some information that appears incorrect or inconsistent. Please remember that this report is a direct function of the data that has been entered at your hospital. Therefore, please check any data issues with your online submitted data. The only caveat to this is that any corrections that you have made to your data since June 30, 2021 will not appear in this report. They will appear in the next quarterly report.

A registry that collects data on mechanical circulatory assist devices is necessarily complex. This complexity is the result of the support that the device provides (left ventricular support, right ventricular support, biventricular support, total heart support) and the potential for multiple exchanges within a patient. The major outcomes are just as complex because the standard outcome of death must be considered in the presence of transplantation and explant due to recovery of the heart. We have organized this report so that the pre-implant data represents all prospective device implants of LVAD, BiVAD or TAH. This is based on the organization of the STS Intermacs web-based data entry and will allow a complete picture of the patients and devices entered for your hospital.

I.C. Statistical Summaries and Benchmarks for Quality Assurance

A primary purpose of this report is to provide statistical summaries of patients enrolled at the local hospital and to provide side-by-side comparisons of the hospital data with the data from the entire STS InterMACS Registry. Therefore these reports will provide the data information component of quality assurance where the hospital can compare both their patient mix with a national standard and will also be able to compare their outcomes after device implant with national results.

STS InterMACS is a valuable source of benchmarking according to what is occurring across the country in the MCS D community. This benchmark is not intended to imply good practice or bad practice but rather allows the hospital to compare the characteristics of their implanted patients with the patients from a national database.

I.D. Registry Compliance

Each hospital is evaluated for compliance and data entry.

I.E. Future Reports

As previously stated, this report is a major step in greatly expanded quarterly reports from STS InterMACS. We will continue expansion of this report which will be the results of our pre-specified plans and feedback from the MCS D community.

Some of our specific plans include statistical summaries according to primary and secondary implants and also according to adult and pediatric patients. We also plan to add a section that summarizes the results of the initial screening log. This will include a frequency of the reasons for failing to obtain informed consent and a comparison to the national experience.

I.F. Report Coverage - Inclusion / Exclusion Criteria

Starting 2020 Q4 the INTERMACS reports have been restructured to provide information from ALL patients enrolled in INTERMACS. To organize the information a series of reports is provided to compare patient characteristics and outcomes of different kinds of patients at your site with the aggregate INTERMACS cohort. The following report versions are created:

- Cumulative - All Patients
- Cumulative - Primary Patients
- Cumulative – Prior VAD Patients
- Recent - All Patients
- Recent - Primary Patients
- Recent – Prior VAD Patients

The CUMULATIVE report versions includes patients enrolled throughout the entire registry and is intended to provide a comprehensive set of long term outcomes. The RECENT report is limited to patients enrolled within the last rolling 6 quarters and provides information on contemporary patients.

The versions of the reports generated for ALL PATIENTS include all patients implanted within the report coverage dates. The PRIMARY PATIENTS versions are limited to patients that do not have a history of prior VAD reported on the pre-implant form of their first INTERMACS enrolled implant. The PRIOR VAD PATIENTS reports are limited to patients in which a prior VAD is indicated on their first enrolled pre-implant form.

There are a few administrative scenarios in which patients are excluded from the CUMULATIVE – ALL PATIENTS Report in order facilitate accurate comparisons to the aggregate INTERMACS data. The following patients are removed from all analyses:

- Retrospective Patients – the patient’s initial implant date is prior to your site’s activation in INTERMACS
- Implant, Pre-Implant, or Patient form not validated – patients missing a fully submitted implant, pre-implant, or patient form are not included because key data elements used in the reporting may be missing.
- Patient Implant Date Outside of Report Coverage Patients implanted prior to the start of data collection June 23, 2006 or after the report coverage stop date December 31, 2020 are not include in the report.
- Pediatric Patients (Age <19 years at implant

Patients that meet these exclusion criteria are listed in “Exhibit 49: Patients Implanted at your Center but Excluded from the Cumulative - All Patient Report

The accompanying Data Quality Report lists all patients enrolled in STS Intermacs at your site.

Transfer patients and their subsequent experience are analyzed in the report for the site that implanted the patients first device enrolled in INTERMACS.

II. Statistical Summaries and Benchmarks for Quality Assurance

The first part of this section contains summary statistics of patients implanted (and enrolled in STS Intermacs) at your hospital. As a benchmark, the corresponding summary statistics for the entire Intermacs Registry are also provided. For explanations and/or definitions of the data elements go to the STS Intermacs User's Guide www.intermacs.org and select 'Intermacs Appendices', Appendix M/User's Guide'.

The summary statistics for continuous variables includes N (the number of patients with data), MEAN (the average value), STD (standard deviation), MIN (the smallest value), and MAX (the largest value).

Exhibit 1: Device Counts for Patients in this Report

The following tables list the number of implants received by patients meeting the inclusion criteria for this report. Subsequent exhibits are based on a patient level analysis. Characteristics are reported at the time of first implant. Unless noted otherwise, outcomes and follow-up include all information reported to INTERMACS for the patient.

NOTE: For most patients a second device indicates a device exchange. However, this count also includes the patients who receive a subsequent RVAD.

GROUP=HOSPX-9999

Device	IMPLANT DATE PERIOD			TOTAL
	< 2014	2014 - 2017	2018 - 2021 (Jan-Jun)	
	n	n	n	
Primary Device	242	301	263	806
2nd Device	30	38	6	74
3rd Device	5	2	0	7
4th Device	0	0	0	0
5th Device	0	0	0	0

GROUP=STS InterMACS

Device	IMPLANT DATE PERIOD			TOTAL
	< 2014	2014 - 2017	2018 - 2021 (Jan-Jun)	
	n	n	n	
Primary Device	11100	11943	10698	33741
2nd Device	1764	1771	528	4063
3rd Device	314	306	53	673
4th Device	45	42	4	91
5th Device	6	4	1	11

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Demographics

Exhibit 2: Age Group

The following tables summarize age groups at your site and STS InterMACS over time.

AGE GROUP (yr)	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
19-39	26	10.7 %	42	13.9 %	26	9.8 %	94	11.6 %	1415	12.7 %	1479	12.3 %	1326	12.3 %	4220	12.5 %
40-59	108	44.6 %	122	40.5 %	112	42.5 %	342	42.4 %	4769	42.9 %	5019	42.0 %	4274	39.9 %	14062	41.6 %
60-79	108	44.6 %	135	44.8 %	123	46.7 %	366	45.4 %	4857	43.7 %	5376	45.0 %	5051	47.2 %	15284	45.2 %
80+	.	.	2	0.6 %	2	0.7 %	4	0.4 %	59	0.5 %	69	0.5 %	47	0.4 %	175	0.5 %
TOTAL	242	100.0 %	301	100.0 %	263	100.0 %	806	100.0 %	11100	100.0 %	11943	100.0 %	10698	100.0 %	33741	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Demographics****Exhibit 3: Gender**

The following tables summarize gender at your site and STS InterMACS over time.

GENDER	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Female	52	21.4 %	73	24.2 %	47	17.8 %	172	21.3 %	2349	21.1 %	2592	21.7 %	2402	22.4 %	7343	21.7 %
Male	190	78.5 %	228	75.7 %	216	82.1 %	634	78.6 %	8750	78.8 %	9333	78.1 %	8293	77.5 %	26376	78.1 %
Unspecified	1	0.0 %	18	0.1 %	3	0.0 %	22	0.0 %
TOTAL	242	100.0 %	301	100.0 %	263	100.0 %	806	100.0 %	11100	100.0 %	11943	100.0 %	10698	100.0 %	33741	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Demographics****Exhibit 4: Race**

The following tables summarize race at your site and STS Intermacs over time. The coordinator may check all that apply.

RACE	HOSPX-9999								STS Intermacs							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
African American	71	29.3 %	115	38.2 %	95	36.1 %	281	34.8 %	2444	22.0 %	3013	25.2 %	3115	29.1 %	8572	25.4 %
Other, Unknown, Undisclosed	45	18.5 %	45	14.9 %	53	20.1 %	143	17.7 %	945	8.5 %	1189	9.9 %	1054	9.8 %	3188	9.4 %
White	126	52.0 %	141	46.8 %	115	43.7 %	382	47.3 %	7711	69.4 %	7741	64.8 %	6529	61.0 %	21981	65.1 %
TOTAL	242	100.0 %	301	100.0 %	263	100.0 %	806	100.0 %	11100	100.0 %	11943	100.0 %	10698	100.0 %	33741	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Demographics****Exhibit 5: Hispanic Ethnicity**

The following tables summarize Hispanic ethnicity at your site and STS InterMACS over time.

HISPANIC ETHNICITY	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Non-Hispanic	205	84.7 %	253	84.0 %	197	74.9 %	655	81.2 %	10389	93.5 %	10818	90.5 %	9632	90.0 %	30839	91.3 %
Unknown	.	.	15	4.9 %	33	12.5 %	48	5.9 %	1	0.0 %	260	2.1 %	356	3.3 %	617	1.8 %
Hispanic	37	15.2 %	33	10.9 %	33	12.5 %	103	12.7 %	710	6.3 %	865	7.2 %	710	6.6 %	2285	6.7 %
TOTAL	242	100.0 %	301	100.0 %	263	100.0 %	806	100.0 %	11100	100.0 %	11943	100.0 %	10698	100.0 %	33741	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Clinical Characteristics****Exhibit 6. BSA**

The following tables summarize body surface area (BSA) at your site and STS Intermacs over time. BSA is a variable that is calculated based on the patient's height and weight. The Boyd calculation is used in this analysis.

GROUP=HOSPX-9999

PRE-IMPLANT BSA		< 2014	2014 - 2017	2018 - 2021 (Jan-Jun)	TOTAL
	N	239	299	262	800
	Mean	2.04	2.00	2.06	2.03
	Std	0.29	0.35	0.32	0.33
	Min	1.12	0.98	1.01	0.98
	Max	3.11	3.05	2.98	3.11

GROUP=STS Intermacs

PRE-IMPLANT BSA		< 2014	2014 - 2017	2018 - 2021 (Jan-Jun)	TOTAL
	N	10975	11890	10662	33527
	Mean	2.08	2.07	2.09	2.08
	Std	0.30	0.32	0.32	0.31
	Min	0.70	0.46	0.47	0.46
	Max	3.44	3.62	3.89	3.89

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Clinical Characteristics

Exhibit 7. Device Strategy

The following tables summarize pre-implant device strategy at your site and STS InterMACS over time.

PRE-IMPLANT DEVICE STRATEGY	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
BTT - Listed	55	22.7 %	52	17.2 %	29	11.0 %	136	16.8 %	3141	28.2 %	3186	26.6 %	1171	10.9 %	7498	22.2 %
BTT - Likely	54	22.3 %	33	10.9 %	18	6.8 %	105	13.0 %	2570	23.1 %	1656	13.8 %	857	8.0 %	5083	15.0 %
BTT - Moderate	34	14.0 %	34	11.2 %	10	3.8 %	78	9.6 %	1138	10.2 %	1002	8.3 %	874	8.1 %	3014	8.9 %
BTT - Unlikely	11	4.5 %	8	2.6 %	3	1.1 %	22	2.7 %	369	3.3 %	274	2.2 %	269	2.5 %	912	2.7 %
Destination Therapy	86	35.5 %	173	57.4 %	198	75.2 %	457	56.6 %	3696	33.2 %	5730	47.9 %	7333	68.5 %	16759	49.6 %
Bridge to Recovery	.	.	1	0.3 %	5	1.9 %	6	0.7 %	116	1.0 %	50	0.4 %	87	0.8 %	253	0.7 %
Rescue Therapy	2	0.8 %	2	0.2 %	66	0.5 %	39	0.3 %	27	0.2 %	132	0.3 %
Other	4	0.0 %	6	0.0 %	80	0.7 %	90	0.2 %
TOTAL	242	100.0 %	301	100.0 %	263	100.0 %	806	100.0 %	11100	100.0 %	11943	100.0 %	10698	100.0 %	33741	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Clinical Characteristics

Exhibit 8. Patient Profile Levels

The following tables summarize pre-implant STS InterMACS patient profile levels at your site and STS InterMACS over time.

PRE-IMPLANT PATIENT PROFILE	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
1 Critical Cardiogenic Shock	48	19.8 %	36	11.9 %	39	14.8 %	123	15.2 %	2121	19.1 %	2307	19.4 %	2011	18.7 %	6439	19.1 %
2 Progressive Decline	89	36.7 %	73	24.2 %	88	33.4 %	250	31.0 %	4203	38.0 %	4091	34.4 %	3528	32.9 %	11822	35.1 %
3 Stable but Inotrope Dependent	73	30.1 %	175	58.1 %	122	46.3 %	370	45.9 %	2795	25.2 %	3998	33.6 %	3822	35.7 %	10615	31.5 %
4 Resting Symptoms	24	9.9 %	16	5.3 %	11	4.1 %	51	6.3 %	1425	12.8 %	1251	10.5 %	1118	10.4 %	3794	11.2 %
5 Exertion Intolerant	6	2.4 %	6	0.7 %	290	2.6 %	165	1.3 %	113	1.0 %	568	1.6 %
6 Exertion Limited	2	0.8 %	.	.	1	0.3 %	3	0.3 %	141	1.2 %	51	0.4 %	49	0.4 %	241	0.7 %
7 Advanced NYHA Class 3	.	.	1	0.3 %	2	0.7 %	3	0.3 %	79	0.7 %	25	0.2 %	57	0.5 %	161	0.4 %
TOTAL	242	100.0 %	301	100.0 %	263	100.0 %	806	100.0 %	11054	100.0 %	11888	100.0 %	10698	100.0 %	33640	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Clinical Characteristics

Exhibit 9a. Medications - IV Inotropes Within 48 Hours of Implant

The following tables summarize IV inotrope therapy within 48 hours prior to implant at your site and STS Intermacs over time.

IV INOTROPES	HOSPX-9999								
	< 2014			2014 - 2017			2018 - 2021 (Jan-Jun)		
	N	Yes	%	N	Yes	%	N	Yes	%
Dobutamine	201	77	38.3%	274	141	51.5%	219	103	47.0%
Dopamine	201	16	8.0%	274	6	2.2%	219	5	2.3%
Milrinone	201	169	84.1%	274	219	79.9%	219	173	79.0%
Levosimendan	201	0	0.0%	274	0	0.0%	219	1	0.5%
Epinephrine	201	8	4.0%	274	22	8.0%	219	24	11.0%
Norepinephrine	201	18	9.0%	274	12	4.4%	219	16	7.3%
Isoproterenol	201	0	0.0%	274	0	0.0%	219	0	0.0%
Other Specify	201	6	3.0%	274	0	0.0%	219	6	2.7%
Unknown	201	0	0.0%	274	0	0.0%	219	2	0.9%

IV INOTROPES	STS Intermacs								
	< 2014			2014 - 2017			2018 - 2021 (Jan-Jun)		
	N	Yes	%	N	Yes	%	N	Yes	%
Dobutamine	8980	3545	39.5%	9951	3715	37.3%	8932	3321	37.2%
Dopamine	8980	1080	12.0%	9951	780	7.8%	8932	401	4.5%
Milrinone	8980	6674	74.3%	9951	7636	76.7%	8932	6795	76.1%
Levosimendan	8980	14	0.2%	9951	7	0.1%	8932	8	0.1%
Epinephrine	8980	563	6.3%	9951	952	9.6%	8932	970	10.9%
Norepinephrine	8980	557	6.2%	9951	803	8.1%	8932	791	8.9%
Isoproterenol	8980	23	0.3%	9951	11	0.1%	8932	12	0.1%
Other Specify	8980	307	3.4%	9951	105	1.1%	8932	87	1.0%
Unknown	8980	11	0.1%	9951	5	0.1%	8932	12	0.1%

IV INOTROPES	HOSPX-9999			STS Intermacs		
	N	Yes	%	N	Yes	%
Dobutamine	694	321	46.3%	27863	10581	38.0%
Dopamine	694	27	3.9%	27863	2261	8.1%
Milrinone	694	561	80.8%	27863	21105	75.7%
Levosimendan	694	1	0.1%	27863	29	0.1%
Epinephrine	694	54	7.8%	27863	2485	8.9%
Norepinephrine	694	46	6.6%	27863	2151	7.7%
Isoproterenol	694	0	0.0%	27863	46	0.2%

(Continued)

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Clinical Characteristics

Exhibit 9a. Medications - IV Inotropes Within 48 Hours of Implant

IV INOTROPES	HOSPX-9999			STS InterMACS		
	N	Yes	%	N	Yes	%
Other Specify	694	12	1.7%	27863	499	1.8%
Unknown	694	2	0.3%	27863	28	0.1%

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Clinical Characteristics****Exhibit 9b. Medications - History and Current Use**

The following tables compare the history and current use of specific medications prior to implant at your site and STS InterMACS.

ACE INHIBITORS	HOSPX-9999		STS InterMACS	
	N	%	N	%
Currently using	113	14.5	6489	19.8
Known previous use (within past year)	164	21.0	6872	21.0
No	325	41.6	16488	50.4
Unknown	180	23.0	2853	8.7
TOTAL	782	100	32702	100

ALDOSTERONE ANTAGONIST	HOSPX-9999		STS InterMACS	
	N	%	N	%
Currently using	276	35.3	11883	36.3
Known previous use (within past year)	177	22.6	5607	17.1
No	226	28.9	13089	40.0
Unknown	103	13.2	2123	6.5
TOTAL	782	100	32702	100

ALLOPURINOL*	HOSPX-9999		STS InterMACS	
	N	%	N	%
Currently using	66	10.0	3350	12.5
Known previous use (within past year)	24	3.6	954	3.6
No	381	57.6	19606	73.2
Unknown	191	28.9	2870	10.7
TOTAL	662	100	26780	100

AMIODARONE	HOSPX-9999		STS InterMACS	
	N	%	N	%
Currently using	295	37.7	13037	39.9
Known previous use (within past year)	64	8.2	2224	6.8
No	311	39.8	15403	47.1
Unknown	112	14.3	2038	6.2
TOTAL	782	100	32702	100

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Clinical Characteristics****Exhibit 9b. Medications - History and Current Use**

ANGIOTENSIN RECEPTOR BLOCKER	HOSPX-9999		STS InterMACS	
	N	%	N	%
Currently using	48	6.1	3090	9.4
Known previous use (within past year)	96	12.3	4188	12.8
No	446	57.0	22047	67.4
Unknown	192	24.6	3377	10.3
TOTAL	782	100	32702	100

ANTIPLATELET THERAPY DRUG	HOSPX-9999		STS InterMACS	
	N	%	N	%
Currently using	325	41.6	17649	54.0
Known previous use (within past year)	125	16.0	4612	14.1
No	239	30.6	8858	27.1
Unknown	93	11.9	1583	4.8
TOTAL	782	100	32702	100

BETA BLOCKERS	HOSPX-9999		STS InterMACS	
	N	%	N	%
Currently using	289	37.0	14444	44.2
Known previous use (within past year)	222	28.4	9535	29.2
No	175	22.4	7319	22.4
Unknown	96	12.3	1404	4.3
TOTAL	782	100	32702	100

WARFARIN (COUMADIN)	HOSPX-9999		STS InterMACS	
	N	%	N	%
Currently using	83	10.6	5054	15.5
Known previous use (within past year)	124	15.9	5729	17.5
No	439	56.1	19503	59.6
Unknown	136	17.4	2416	7.4
TOTAL	782	100	32702	100

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Clinical Characteristics****Exhibit 9b. Medications - History and Current Use**

NESIRITIDE	HOSPX-9999		STS InterMACS	
	N	%	N	%
No	692	90.1	30211	94.4
Unknown	72	9.4	1259	3.9
Yes	4	0.5	541	1.7
TOTAL	768	100	32011	100

NITRIC OXIDE	HOSPX-9999		STS InterMACS	
	N	%	N	%
No	698	89.3	30371	92.9
Unknown	69	8.8	1277	3.9
Yes	15	1.9	1054	3.2
TOTAL	782	100	32702	100

LOOP DIURETICS	HOSPX-9999		STS InterMACS	
	N	%	N	%
No	93	11.9	4879	14.9
Unknown	51	6.5	416	1.3
Yes	638	81.6	27407	83.8
TOTAL	782	100	32702	100

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Clinical Characteristics****Exhibit 9b. Medications - History and Current Use**

PRE-IMPLANT LOOP DIURETIC TYPE*	HOSPX-9999			STS Intermacs		
	N	Yes	%	N	Yes	%
Furosemide	498	339	68.07%	21249	12536	59.00%
Torsemide	498	59	11.85%	21249	4112	19.35%
Bumetanide	498	101	20.28%	21249	4787	22.53%
Other	498	0	0.00%	21249	94	0.44%

CARDIAC RESYNCHRONIZATION THERAPY (CRT)*	HOSPX-9999		STS Intermacs	
	N	%	N	%
No	435	67.1	17615	67.6
Unknown	93	14.4	1670	6.4
Yes	120	18.5	6758	25.9
TOTAL	648	100	26043	100

METALOZONE / THIAZIDE*	HOSPX-9999		STS Intermacs	
	N	%	N	%
No	458	69.2	22658	84.7
Unknown	134	20.2	992	3.7
Yes	70	10.6	3101	11.6
TOTAL	662	100	26751	100

METALOZONE / THIAZIDE - FREQUENCY*	HOSPX-9999		STS Intermacs	
	N	%	N	%
Regular	31	44.3	1299	41.9
Intermittent	39	55.7	1801	58.1
TOTAL	70	100	3100	100

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Clinical Characteristics****Exhibit 10. Laboratories**

The following tables summarize pre-implant laboratories at your site and STS Intermacs.

		HOSPX-9999	STS Intermacs
Sodium (mEq/L)	N	782	32636
	Mean	134.59	135.02
	Std	5.19	4.88
	Min	117.00	110.00
	Max	154.00	161.00
Potassium (mEq/L)	N	782	32632
	Mean	4.16	4.07
	Std	0.48	0.48
	Min	2.60	2.00
	Max	6.10	7.00
BUN (mg/dL)	N	782	32581
	Mean	31.19	29.59
	Std	19.45	18.04
	Min	1.11	0.70
	Max	336.00	336.12
Creatinine (mg/dL)	N	782	32624
	Mean	1.48	1.41
	Std	0.74	0.72
	Min	0.50	0.00
	Max	9.10	15.00
Alanine Aminotransferase/ALT (u/L)	N	705	30999
	Mean	69.29	70.14
	Std	178.12	229.68
	Min	4.00	1.00
	Max	2395.00	9930.00
Aspartate Aminotransferase/AST (u/L)	N	704	30992
	Mean	60.47	62.59
	Std	185.22	243.64
	Min	2.00	2.00
	Max	3982.00	10000.00
LDH (µkat/L), (U/L)	N	406	16615
	Mean	515.30	405.02
	Std	534.95	466.09
	Min	19.00	0.00
	Max	6454.00	18345.00
All	N	806	33741

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Clinical Characteristics****Exhibit 10. Laboratories**

PRE-IMPLANT LABORATORIES		HOSPX-9999	STS Intermacs
Total Bilirubin (mg/dL)	N	704	30949
	Mean	1.48	1.42
	Std	1.89	1.91
	Min	0.10	0.08
	Max	27.20	52.00
Albumin (g/dL)	N	681	30576
	Mean	3.55	3.39
	Std	0.68	0.65
	Min	0.37	0.00
	Max	8.00	8.00
Pre-albumin (mg/dL)	N	423	17254
	Mean	18.40	18.29
	Std	7.88	7.36
	Min	3.00	3.00
	Max	55.00	60.00
Total Cholesterol (mg/dL)	N	515	18408
	Mean	127.08	128.76
	Std	42.31	100.30
	Min	51.40	50.00
	Max	410.00	7413.13
Brain Natriuretic Peptide (pg/mL)	N	12	14073
	Mean	2014.75	1240.22
	Std	1459.63	1142.53
	Min	91.00	1.00
	Max	4253.00	7500.00
Pro Brain Natriuretic Peptide (pg/mL)	N	522	8278
	Mean	6847.37	6885.73
	Std	7146.15	8036.55
	Min	27.00	26.00
	Max	60000.00	60000.00
White Blood Cell Count (x10/ μ L)	N	775	32570
	Mean	9.30	8.86
	Std	4.61	4.25
	Min	2.50	1.00
	Max	68.00	96.00
Hemoglobin (g/dL)	N	777	32571
	Mean	10.80	11.09
	Std	2.22	2.18
	Min	0.78	0.10
	Max	19.70	20.00
All	N	806	33741

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Clinical Characteristics****Exhibit 10. Laboratories**

PRE-IMPLANT LABORATORIES		HOSPX-9999	STS InterMACs
Platelets (x10/ μ L)	N	778	32553
	Mean	200.43	194.80
	Std	89.07	82.14
	Min	13.00	0.00
	Max	738.00	800.00
INR	N	754	31288
	Mean	1.32	1.32
	Std	0.61	0.52
	Min	0.90	0.50
	Max	13.70	15.00
Sensitivity CRP (mg/L)	N	131	8768
	Mean	45.09	23.66
	Std	62.34	46.92
	Min	0.10	0.00
	Max	300.00	800.00
All	N	806	33741

PRE-IMPLANT LUPUS ANTICOAGULANT STATUS*	HOSPX-9999		STS InterMACs	
	N	%	N	%
Negative	9	1.4	2664	9.9
Positive	3	0.5	336	1.3
Unknown	650	98.2	23801	88.8
TOTAL	662	100	26801	100

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Comorbidities and Potential Barriers to Heart Transplant****Exhibit 11. Pre-Implant Comorbidities**

The following tables compares pre-implant comorbidities at the time of durable MCSD implant between your site and STS InterMACS over time. This section was revised during the v6.0 launch (11/24/20) and includes mapped data from patients implanted 2012 and later. Information on Prior Sternotomy and History of Hematopoietic Cancer is currently being mapped and will be available in the reports starting next quarter.

Cardiothoracic issues	HOSPX-9999								
	< 2014			2014 - 2017			2018 - 2021 (Jan-Jun)		
	N	Yes	%	N	Yes	%	N	Yes	%
Frequent ICD Shocks	122	4	3.3%	301	13	4.3%	232	4	1.7%
Chronic Lung Disease	237	27	11.4%	301	12	4.0%	236	16	6.8%
Pulmonary Hypertension	127	42	33.1%	301	28	9.3%	236	48	20.3%
Recent Pulmonary Embolus	123	2	1.6%	301	0	0.0%	236	1	0.4%
History of Atrial Arrhythmia	122	22	18.0%	301	48	15.9%	233	38	16.3%
Thoracic Aortic Disease	122	1	0.8%	301	2	0.7%	235	6	2.6%

Cardiothoracic issues	STS InterMACS								
	< 2014			2014 - 2017			2018 - 2021 (Jan-Jun)		
	N	Yes	%	N	Yes	%	N	Yes	%
Frequent ICD Shocks	5498	327	5.9%	11942	606	5.1%	9631	393	4.1%
Chronic Lung Disease	10941	1264	11.6%	11942	1081	9.1%	9631	860	8.9%
Pulmonary Hypertension	5937	1791	30.2%	11942	2402	20.1%	9627	1754	18.2%
Recent Pulmonary Embolus	5514	108	2.0%	11942	195	1.6%	9650	132	1.4%
History of Atrial Arrhythmia	5499	1170	21.3%	11942	2431	20.4%	9639	1840	19.1%
Thoracic Aortic Disease	5506	68	1.2%	11942	159	1.3%	9640	60	0.6%

Cardiothoracic issues	HOSPX-9999			STS InterMACS		
	N	Yes	%	N	Yes	%
Frequent ICD Shocks	647	21	3.2%	26370	1295	4.9%
Chronic Lung Disease	655	36	5.5%	26750	2467	9.2%
Pulmonary Hypertension	651	113	17.4%	26395	5394	20.4%
Recent Pulmonary Embolus	651	2	0.3%	26390	415	1.6%
History of Atrial Arrhythmia	648	107	16.5%	26378	5309	20.1%
Thoracic Aortic Disease	650	9	1.4%	26379	270	1.0%

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Comorbidities and Potential Barriers to Heart Transplant

Exhibit 11. Pre-Implant Comorbidities

Nutritional/GI issues	HOSPX-9999								
	< 2014			2014 - 2017			2018 - 2021 (Jan-Jun)		
	N	Yes	%	N	Yes	%	N	Yes	%
Severe Diabetes	177	59	33.3%	301	48	15.9%	239	33	13.8%
Malnutrition/Cachexia	128	6	4.7%	301	1	0.3%	238	4	1.7%
History GI Ulcers	122	0	0.0%	301	0	0.0%	233	1	0.4%
Liver Dysfunction	5	0	0.0%	290	2	0.7%	232	12	5.2%
Hepatitis	234	30	12.8%	301	1	0.3%	236	1	0.4%

Nutritional/GI issues	STS Intermacs								
	< 2014			2014 - 2017			2018 - 2021 (Jan-Jun)		
	N	Yes	%	N	Yes	%	N	Yes	%
Severe Diabetes	7560	1766	23.4%	11943	1135	9.5%	9656	1004	10.4%
Malnutrition/Cachexia	5589	256	4.6%	11943	323	2.7%	9641	277	2.9%
History GI Ulcers	5499	71	1.3%	11943	73	0.6%	9642	68	0.7%
Liver Dysfunction	316	7	2.2%	11169	505	4.5%	9642	362	3.8%
Hepatitis	10782	365	3.4%	11943	147	1.2%	9642	113	1.2%

Nutritional/GI issues	HOSPX-9999			STS Intermacs		
	N	Yes	%	N	Yes	%
Severe Diabetes	656	107	16.3%	26543	2707	10.2%
Malnutrition/Cachexia	654	6	0.9%	26390	769	2.9%
History GI Ulcers	648	1	0.2%	26382	203	0.8%
Liver Dysfunction	527	14	2.7%	21023	872	4.1%
Hepatitis	656	3	0.5%	26740	352	1.3%

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Comorbidities and Potential Barriers to Heart Transplant

Exhibit 11. Pre-Implant Comorbidities

Vascular issues	HOSPX-9999								
	< 2014			2014 - 2017			2018 - 2021 (Jan-Jun)		
	N	Yes	%	N	Yes	%	N	Yes	%
Heparin-induced Thrombocytopenia	122	1	0.8%	301	2	0.7%	234	2	0.9%
Chronic Coagulopathy	122	1	0.8%	301	1	0.3%	233	0	0.0%
Cerebrovascular Disease	239	42	17.6%	301	15	5.0%	237	12	5.1%
Major Stroke	235	19	8.1%	301	10	3.3%	224	9	4.0%
Peripheral Arterial Disease	234	13	5.6%	301	2	0.7%	238	6	2.5%

Vascular issues	STS InterMACS								
	< 2014			2014 - 2017			2018 - 2021 (Jan-Jun)		
	N	Yes	%	N	Yes	%	N	Yes	%
Heparin-induced Thrombocytopenia	5536	125	2.3%	11942	118	1.0%	9621	103	1.1%
Chronic Coagulopathy	5499	52	0.9%	11942	154	1.3%	9625	98	1.0%
Cerebrovascular Disease	11045	1394	12.6%	11942	678	5.7%	9648	535	5.5%
Major Stroke	10883	662	6.1%	11899	447	3.8%	9016	368	4.1%
Peripheral Arterial Disease	10956	591	5.4%	11942	514	4.3%	9642	385	4.0%

Vascular issues	HOSPX-9999			STS InterMACS		
	N	Yes	%	N	Yes	%
Heparin-induced Thrombocytopenia	649	5	0.8%	26361	300	1.1%
Chronic Coagulopathy	648	2	0.3%	26364	300	1.1%
Cerebrovascular Disease	657	37	5.6%	26770	1608	6.0%
Major Stroke	644	27	4.2%	26058	1047	4.0%
Peripheral Arterial Disease	657	16	2.4%	26762	1171	4.4%

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Comorbidities and Potential Barriers to Heart Transplant

Exhibit 11. Pre-Implant Comorbidities

Oncology/infection issues	HOSPX-9999								
	< 2014			2014 - 2017			2018 - 2021 (Jan-Jun)		
	N	Yes	%	N	Yes	%	N	Yes	%
History Solid Organ Cancer	130	8	6.2%	301	14	4.7%	238	10	4.2%
Currently has Cancer v6	0	.	.	0	.	.	12	0	0.0%
History of Solid Organ Transplant v6	0	.	.	0	.	.	14	0	0.0%
History of Bone Marrow Transplant (BMT)	122	0	0.0%	301	0	0.0%	239	0	0.0%
HIV	122	1	0.8%	300	0	0.0%	225	2	0.9%

Oncology/infection issues	STS InterMACS								
	< 2014			2014 - 2017			2018 - 2021 (Jan-Jun)		
	N	Yes	%	N	Yes	%	N	Yes	%
History Solid Organ Cancer	5927	489	8.3%	11942	541	4.5%	9656	478	5.0%
Currently has Cancer v6	38	0	0.0%	44	0	0.0%	720	13	1.8%
History of Solid Organ Transplant v6	38	0	0.0%	44	0	0.0%	734	5	0.7%
History of Bone Marrow Transplant (BMT)	5500	3	0.1%	11943	11	0.1%	9652	16	0.2%
HIV	5497	16	0.3%	11892	36	0.3%	8953	51	0.6%

Oncology/infection issues	HOSPX-9999			STS InterMACS		
	N	Yes	%	N	Yes	%
History Solid Organ Cancer	653	28	4.3%	26426	1302	4.9%
Currently has Cancer v6	12	0	0.0%	798	13	1.6%
History of Solid Organ Transplant v6	14	0	0.0%	812	5	0.6%
History of Bone Marrow Transplant (BMT)	654	0	0.0%	26392	30	0.1%
HIV	639	3	0.5%	25642	101	0.4%

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Comorbidities and Potential Barriers to Heart Transplant

Exhibit 11. Pre-Implant Comorbidities

Data collection for the psychosocial issues section changed structure as a part of the v6.0 release. Mapping of this data is underway and this information will be available in the reports starting next quarter.

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Comorbidities and Potential Barriers to Heart Transplant

Exhibit 12. Pre-Implant Potential Barriers to Heart Transplant

The following tables compare pre-implant potential barriers to heart transplant at your site and STS Intermacs over time. This section was revised during the v6.0 launch (11/24/20) and includes mapped data from patients implanted 2012 and later.

Potential Barriers to Heart Transplant	HOSPX-9999								
	< 2014			2014 - 2017			2018 - 2021 (Jan-Jun)		
	N	Yes	%	N	Yes	%	N	Yes	%
Advanced Age	240	29	12.1%	301	45	15.0%	239	23	9.6%
Frailty	240	5	2.1%	301	19	6.3%	236	8	3.4%
Patient Does Not Want Transplant	240	8	3.3%	301	1	0.3%	234	2	0.9%
Musculoskeletal Limitation to Ambulation	240	0	0.0%	301	0	0.0%	236	0	0.0%
Contraindications to Immunosuppression	240	0	0.0%	301	0	0.0%	235	0	0.0%
Allosensitization	240	0	0.0%	301	0	0.0%	234	3	1.3%
Chronic Renal Disease	240	28	11.7%	301	14	4.7%	236	4	1.7%
Large BMI	240	18	7.5%	301	36	12.0%	239	25	10.5%
Chronic Infectious Concerns	240	0	0.0%	301	0	0.0%	234	1	0.4%

Potential Barriers to Heart Transplant	STS Intermacs								
	< 2014			2014 - 2017			2018 - 2021 (Jan-Jun)		
	N	Yes	%	N	Yes	%	N	Yes	%
Advanced Age	10949	1371	12.5%	11943	1479	12.4%	9633	1457	15.1%
Frailty	10950	404	3.7%	11943	594	5.0%	9615	562	5.8%
Patient Does Not Want Transplant	10949	208	1.9%	11943	199	1.7%	9550	178	1.9%
Musculoskeletal Limitation to Ambulation	10950	42	0.4%	11943	42	0.4%	9615	43	0.4%
Contraindications to Immunosuppression	10950	59	0.5%	11942	37	0.3%	9596	42	0.4%
Allosensitization	10950	78	0.7%	11942	56	0.5%	9570	83	0.9%
Chronic Renal Disease	10949	940	8.6%	11943	904	7.6%	9621	721	7.5%
Large BMI	10949	1065	9.7%	11943	1352	11.3%	9635	1419	14.7%
Chronic Infectious Concerns	10950	76	0.7%	11942	102	0.9%	9615	94	1.0%

Potential Barriers to Heart Transplant	HOSPX-9999			STS Intermacs		
	N	Yes	%	N	Yes	%
Advanced Age	659	89	13.5%	26746	3705	13.9%
Frailty	656	28	4.3%	26729	1352	5.1%
Patient Does Not Want Transplant	654	8	1.2%	26664	493	1.8%
Musculoskeletal Limitation to Ambulation	656	0	0.0%	26729	106	0.4%
Contraindications to Immunosuppression	655	0	0.0%	26709	110	0.4%
Allosensitization	654	3	0.5%	26683	180	0.7%

(Continued)

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Comorbidities and Potential Barriers to Heart Transplant

Exhibit 12. Pre-Implant Potential Barriers to Heart Transplant

Potential Barriers to Heart Transplant	HOSPX-9999			STS InterMACS		
	N	Yes	%	N	Yes	%
Chronic Renal Disease	656	30	4.6%	26734	2030	7.6%
Large BMI	659	71	10.8%	26748	3288	12.3%
Chronic Infectious Concerns	654	1	0.2%	26728	229	0.9%

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Hemodynamics****Exhibit 13. General Hemodynamics**

The following table summarizes pre-implant heart rate, systolic BP and diastolic BP at your site and STS InterMACS.

PRE-IMPLANT GENERAL HEMODYNAMICS		HOSPX-9999	STS InterMACS
Heart Rate	N	781	32482
	Mean	92.04	90.00
	Std	17.37	17.89
	Min	55.00	31.00
	Max	175.00	198.00
Diastolic Blood Pressure (mmHg)	N	763	31903
	Mean	65.44	65.65
	Std	11.85	11.75
	Min	25.00	20.00
	Max	110.00	120.00
Systolic Blood Pressure (mmHg)	N	768	32019
	Mean	105.44	105.20
	Std	16.77	16.40
	Min	53.00	44.00
	Max	163.00	193.00
All	N	806	33741

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Hemodynamics

Exhibit 14a. Echo Hemodynamics - LVEDD

The following tables summarizes pre-implant LVEDD at your site and STS Intermacs over time.

GROUP=HOSPX-9999

PRE-IMPLANT LVEDD (cm)		< 2014	2014 - 2017	2018 - 2021 (Jan-Jun)	TOTAL
	N	199	273	217	689
	Mean	6.57	6.83	6.66	6.70
	Std	1.21	1.07	1.10	1.13
	Min	1.10	3.74	3.21	1.10
	Max	10.00	10.10	9.50	10.10

GROUP=STS Intermacs

PRE-IMPLANT LVEDD (cm)		< 2014	2014 - 2017	2018 - 2021 (Jan-Jun)	TOTAL
	N	7699	9416	7877	24992
	Mean	6.79	6.78	6.73	6.77
	Std	1.18	1.13	1.08	1.13
	Min	1.00	1.20	1.60	1.00
	Max	10.00	20.00	15.00	20.00

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Hemodynamics

Exhibit 14b. Echo Hemodynamics - LVEF

The following tables summarizes pre-implant LVEF at your site and STS InterMACS over time.

PRE-IMPLANT LVEF	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
> 50 (normal)	1	0.4 %	2	0.6 %	.	.	3	0.3 %	67	0.6 %	33	0.2 %	26	0.2 %	126	0.3 %
40-49 (mild)	1	0.4 %	2	0.6 %	.	.	3	0.3 %	60	0.5 %	59	0.4 %	36	0.3 %	155	0.4 %
30-39 (moderate)	22	9.6 %	9	2.9 %	8	3.3 %	39	5.0 %	431	4.2 %	415	3.4 %	314	3.2 %	1160	3.6 %
20-29 (moderate/severe)	77	33.9 %	68	22.5 %	52	21.7 %	197	25.6 %	2332	22.7 %	2911	24.3 %	2360	24.4 %	7603	23.8 %
< 20 (severe)	113	49.7 %	205	68.1 %	177	74.0 %	495	64.5 %	6819	66.5 %	7932	66.4 %	6520	67.5 %	21271	66.7 %
Not Recorded or Not Documented	12	5.2 %	10	3.3 %	2	0.8 %	24	3.1 %	478	4.6 %	531	4.4 %	367	3.7 %	1376	4.3 %
Unknown	1	0.4 %	5	1.6 %	.	.	6	0.7 %	57	0.5 %	62	0.5 %	36	0.3 %	155	0.4 %
TOTAL	227	100.0 %	301	100.0 %	239	100.0 %	767	100.0 %	10244	100.0 %	11943	100.0 %	9659	100.0 %	31846	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Hemodynamics****Exhibit 14c. Echo Hemodynamics - RVEF**

The following tables summarizes pre-implant RVEF at your site and STS Intermacs over time.

PRE-IMPLANT RVEF	HOSPX-9999								STS Intermacs							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Normal	27	11.8 %	71	23.5 %	63	26.3 %	161	20.9 %	1461	14.2 %	2457	20.5 %	2171	22.4 %	6089	19.1 %
Mild	15	6.6 %	76	25.2 %	81	33.8 %	172	22.4 %	1380	13.4 %	2664	22.3 %	2331	24.1 %	6375	20.0 %
Moderate	37	16.2 %	75	24.9 %	61	25.5 %	173	22.5 %	1909	18.6 %	2854	23.8 %	2324	24.0 %	7087	22.2 %
Severe	21	9.2 %	34	11.2 %	12	5.0 %	67	8.7 %	1214	11.8 %	1535	12.8 %	1223	12.6 %	3972	12.4 %
Not Done	65	28.6 %	17	5.6 %	4	1.6 %	86	11.2 %	2745	26.7 %	1512	12.6 %	933	9.6 %	5190	16.2 %
Not Applicable (v4)	.	.	2	0.6 %	2	0.8 %	4	0.5 %	.	.	25	0.2 %	24	0.2 %	49	0.1 %
Unknown	62	27.3 %	26	8.6 %	16	6.6 %	104	13.5 %	1535	14.9 %	896	7.5 %	653	6.7 %	3084	9.6 %
TOTAL	227	100.0 %	301	100.0 %	239	100.0 %	767	100.0 %	10244	100.0 %	11943	100.0 %	9659	100.0 %	31846	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Hemodynamics****Exhibit 14d. Echo Hemodynamics - Mitral Regurgitation**

The following tables summarizes pre-implant mitral regurgitation at your site and STS InterMACS over time.

PRE-IMPLANT MITRAL REGURGITATION	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
0 (none)	15	6.6 %	28	9.3 %	28	11.7 %	71	9.2 %	783	7.6 %	873	7.3 %	743	7.6 %	2399	7.5 %
1 (mild)	94	41.4 %	103	34.2 %	83	34.7 %	280	36.5 %	3341	32.6 %	3892	32.5 %	3260	33.7 %	10493	32.9 %
2 (moderate)	75	33.0 %	93	30.8 %	63	26.3 %	231	30.1 %	3229	31.5 %	3653	30.5 %	2939	30.4 %	9821	30.8 %
3 (severe)	33	14.5 %	52	17.2 %	51	21.3 %	136	17.7 %	2224	21.7 %	2652	22.2 %	2028	20.9 %	6904	21.6 %
Not Recorded or Not Documented	10	4.4 %	25	8.3 %	14	5.8 %	49	6.3 %	578	5.6 %	873	7.3 %	689	7.1 %	2140	6.7 %
~Unknown~	89	0.8 %	89	0.2 %
TOTAL	227	100.0 %	301	100.0 %	239	100.0 %	767	100.0 %	10244	100.0 %	11943	100.0 %	9659	100.0 %	31846	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Hemodynamics****Exhibit 14e. Echo Hemodynamics - Aortic Regurgitation**

The following tables summarizes pre-implant aortic regurgitation at your site and STS InterMACS over time.

PRE-IMPLANT AORTIC REGURGITATION	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
0 (none)	136	59.9 %	165	54.8 %	88	36.8 %	389	50.7 %	5982	58.3 %	6484	54.2 %	5168	53.5 %	17634	55.3 %
1 (mild)	63	27.7 %	71	23.5 %	61	25.5 %	195	25.4 %	2524	24.6 %	3291	27.5 %	2805	29.0 %	8620	27.0 %
2 (moderate)	7	3.0 %	12	3.9 %	5	2.0 %	24	3.1 %	338	3.2 %	410	3.4 %	338	3.4 %	1086	3.4 %
3 (severe)	1	0.4 %	2	0.6 %	3	1.2 %	6	0.7 %	69	0.6 %	66	0.5 %	65	0.6 %	200	0.6 %
Not Recorded or Not Documented	20	8.8 %	51	16.9 %	82	34.3 %	153	19.9 %	1331	12.9 %	1692	14.1 %	1283	13.2 %	4306	13.5 %
TOTAL	227	100.0 %	301	100.0 %	239	100.0 %	767	100.0 %	10244	100.0 %	11943	100.0 %	9659	100.0 %	31846	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Hemodynamics****Exhibit 14f. Echo Hemodynamics - Tricuspid Regurgitation**

The following tables summarizes pre-implant tricuspid regurgitation at your site and STS Intermacs over time.

PRE-IMPLANT TRICUSPID REGURGITATION	HOSPX-9999								STS Intermacs							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
0 (none)	23	10.1 %	26	8.6 %	32	13.3 %	81	10.5 %	1046	10.2 %	978	8.1 %	962	9.9 %	2986	9.3 %
1 (mild)	115	50.6 %	120	39.8 %	111	46.4 %	346	45.1 %	4182	40.8 %	5358	44.8 %	4263	44.1 %	13803	43.3 %
2 (moderate)	69	30.3 %	89	29.5 %	65	27.1 %	223	29.0 %	2991	29.1 %	3279	27.4 %	2590	26.8 %	8860	27.8 %
3 (severe)	10	4.4 %	43	14.2 %	17	7.1 %	70	9.1 %	1240	12.1 %	1370	11.4 %	1064	11.0 %	3674	11.5 %
Not Recorded or Not Documented	10	4.4 %	23	7.6 %	14	5.8 %	47	6.1 %	639	6.2 %	958	8.0 %	780	8.0 %	2377	7.4 %
~Unknown~	146	1.4 %	146	0.4 %
TOTAL	227	100.0 %	301	100.0 %	239	100.0 %	767	100.0 %	10244	100.0 %	11943	100.0 %	9659	100.0 %	31846	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Hemodynamics****Exhibit 15. Swan Hemodynamics**

The following table summarizes pre-implant hemodynamics derived from a Swan-Ganz catheter at your site and STS InterMACS.

PRE-IMPLANT SWAN HEMODYNAMICS		HOSPX-9999	STS InterMACS
Pulmonary Artery Systolic Pressure (mmHg)	N	678	27114
	Mean	49.60	49.53
	Std	14.25	14.90
	Min	1.00	0.00
	Max	90.00	100.00
Pulmonary Artery Diastolic Pressure (mmHg)	N	678	26980
	Mean	24.25	24.94
	Std	8.09	8.85
	Min	2.00	0.00
	Max	60.00	60.00
~Mean RA Pressure (mmHg)~	N	543	20736
	Mean	20.32	13.11
	Std	12.17	8.32
	Min	0.00	-4.00
	Max	54.00	55.00
Mean Pulmonary Artery Capillary Wedge Pressure (mmHg)	N	500	21197
	Mean	24.12	24.86
	Std	9.61	9.27
	Min	2.00	0.00
	Max	50.00	50.00
Cardiac Index	N	581	21955
	Mean	2.39	2.19
	Std	1.21	1.47
	Min	0.60	0.17
	Max	17.00	176.00
Cardiac Output (L/min)	N	651	25379
	Mean	4.49	4.24
	Std	1.60	1.45
	Min	0.40	0.33
	Max	13.10	15.01
All	N	806	33741

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Hemodynamics****Exhibit 16. ECG Cardiac Rhythm**

The following tables summarizes pre-implant ECG cardiac rhythm at your site and STS InterMACS.

ECG CARDIAC RHYTHM	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Sinus	109	45.0 %	127	42.1 %	141	58.9 %	377	48.2 %	4708	42.4 %	5855	49.0 %	5300	54.8 %	15863	48.5 %
Atrial fibrillation	19	7.8 %	32	10.6 %	17	7.1 %	68	8.6 %	993	8.9 %	994	8.3 %	662	6.8 %	2649	8.1 %
Atrial Flutter	1	0.4 %	5	1.6 %	2	0.8 %	8	1.0 %	107	0.9 %	121	1.0 %	103	1.0 %	331	1.0 %
Not done	2	0.8 %	3	0.9 %	2	0.8 %	7	0.8 %	160	1.4 %	194	1.6 %	126	1.3 %	480	1.4 %
Atrial Paced, Ventricular Sensed	3	1.2 %	2	0.6 %	5	2.0 %	10	1.2 %	89	0.8 %	246	2.0 %	192	1.9 %	527	1.6 %
Atrial Sensed, Ventricular Paced	21	8.6 %	70	23.2 %	28	11.7 %	119	15.2 %	693	6.2 %	2096	17.5 %	1535	15.8 %	4324	13.2 %
Atrial Paced, Ventricular Paced	5	2.0 %	20	6.6 %	24	10.0 %	49	6.2 %	331	2.9 %	1177	9.8 %	857	8.8 %	2365	7.2 %
Junctional (v6)	1	0.0 %	1	0.0 %
Unknown	4	1.6 %	5	1.6 %	3	1.2 %	12	1.5 %	293	2.6 %	275	2.3 %	204	2.1 %	772	2.3 %
Other, specify	78	32.2 %	37	12.2 %	17	7.1 %	132	16.8 %	3726	33.5 %	985	8.2 %	679	7.0 %	5390	16.4 %
TOTAL	242	100.0 %	301	100.0 %	239	100.0 %	782	100.0 %	11100	100.0 %	11943	100.0 %	9659	100.0 %	32702	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life****Exhibit 17a. Functional Capacity - NYHA Class**

The following table summarizes the pre-implant NYHA Class at your site and STS InterMACS over time.

PRE-IMPLANT NYHA CLASS	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Class I	1	0.4 %	1	0.1 %	13	0.1 %	14	0.1 %	24	0.2 %	51	0.1 %
Class II	1	0.4 %	2	0.6 %	7	2.9 %	10	1.2 %	46	0.4 %	108	0.9 %	138	1.4 %	292	0.8 %
Class III	40	16.5 %	39	12.9 %	21	8.7 %	100	12.7 %	1889	17.0 %	1696	14.2 %	1216	12.5 %	4801	14.6 %
Class IV	186	76.8 %	251	83.3 %	205	85.7 %	642	82.0 %	8195	73.8 %	9656	80.8 %	8083	83.6 %	25934	79.3 %
Unknown	15	6.1 %	9	2.9 %	5	2.0 %	29	3.7 %	953	8.5 %	468	3.9 %	198	2.0 %	1619	4.9 %
TOTAL	242	100.0 %	301	100.0 %	239	100.0 %	782	100.0 %	11096	100.0 %	11942	100.0 %	9659	100.0 %	32697	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life****Exhibit 17b. Functional Capacity - VO2 Max**

The following table summarizes the pre-implant VO2 max at your site and STS InterMACS.

VO2 MAX		HOSPX-9999	STS InterMACS
VO2 Max (mL/kg/min)	N	17	2840
	Mean	11.81	17.99
	Std	6.61	97.07
	Min	4.00	0.00
	Max	35.00	2800.00
All	N	806	33741

The following table summarizes the reasons the pre-implant VO2 max was incomplete at your site and STS InterMACS.

VO2 MAX - Reason for Incomplete	HOSPX-9999		STS InterMACS	
	N	%	N	%
Not Done: Other	374	48.9	13283	44.5
Not Done: Too Sick	235	30.7	13205	44.2
Unknown	156	20.4	3373	11.3
TOTAL	765	100	29861	100

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life****Exhibit 17c. Functional Capacity - R Value at Peak**

The following table summarizes the pre-implant R value at peak at your site and STS InterMACS.

R VALUE AT PEAK		HOSPX-9999	STS InterMACS
Peak R (%)	N	14	1730
	Mean	6.27	5.74
	Std	13.80	15.02
	Min	1.00	0.70
	Max	52.00	132.00
All	N	806	33741

The following table summarizes the reasons the pre-implant R value at peak was incomplete at your site and InterMACS.

R VALUE AT PEAK - Reason for Incomplete	HOSPX-9999		STS InterMACS	
	N	%	N	%
Not Done	557	72.5	26934	87.0
Unknown	211	27.5	4037	13.0
TOTAL	768	100	30971	100

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life****Exhibit 17d. Functional Capacity - Six Minute Walk**

The following table summarizes the pre-implant six minute walk at your site and STS InterMACS.

6 MINUTE WALK		HOSPX-9999	STS InterMACS
Six Minute Walk (ft)	N	140	6077
	Mean	759.09	829.14
	Std	333.02	1485.67
	Min	0.00	0.00
	Max	1500.00	110892.00
All	N	806	33741

The following table summarizes the reasons the pre-implant six minute walk was incomplete at your site and STS InterMACS.

6 MINUTE WALK - Reason for Incomplete	HOSPX-9999		STS InterMACS	
	N	%	N	%
Not Done: Other	209	32.6	8947	33.6
Not Done: Too Sick	337	52.5	16112	60.5
Unknown	96	15.0	1565	5.9
TOTAL	642	100	26624	100

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life****Exhibit 18a. Quality of Life - EQ-5D Mobility**

The following table compares the EQ-5D Mobility domain between your site and STS InterMACS.

EQ-5D Mobility	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
I have no problems in walking about	29	19.8 %	74	44.8 %	23	32.3 %	126	32.9 %	1616	28.0 %	1978	32.4 %	1628	35.4 %	5222	31.7 %
I have some problems in walking about	87	59.5 %	74	44.8 %	36	50.7 %	197	51.5 %	3157	54.7 %	3172	52.0 %	2269	49.4 %	8598	52.2 %
I am confined to bed	29	19.8 %	16	9.6 %	11	15.4 %	56	14.6 %	916	15.8 %	819	13.4 %	543	11.8 %	2278	13.8 %
Unknown	1	0.6 %	1	0.6 %	1	1.4 %	3	0.7 %	76	1.3 %	124	2.0 %	151	3.2 %	351	2.1 %
TOTAL	146	100.0 %	165	100.0 %	71	100.0 %	382	100.0 %	5765	100.0 %	6093	100.0 %	4591	100.0 %	16449	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life****Exhibit 18b. Quality of Life - EQ-5D Self Care**

The following table compares the EQ-5D Self Care domain between your site and STS InterMACS.

EQ-5D Self Care	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
I have no problems with self-care	73	50.0 %	96	58.1 %	39	54.9 %	208	54.4 %	3136	54.3 %	3427	56.2 %	2598	56.5 %	9161	55.6 %
I have some problems washing or dressing myself	49	33.5 %	48	29.0 %	20	28.1 %	117	30.6 %	1856	32.1 %	1899	31.1 %	1370	29.8 %	5125	31.1 %
I am unable to wash or dress myself	22	15.0 %	20	12.1 %	11	15.4 %	53	13.8 %	696	12.0 %	651	10.6 %	472	10.2 %	1819	11.0 %
Unknown	2	1.3 %	1	0.6 %	1	1.4 %	4	1.0 %	77	1.3 %	116	1.9 %	151	3.2 %	344	2.0 %
TOTAL	146	100.0 %	165	100.0 %	71	100.0 %	382	100.0 %	5765	100.0 %	6093	100.0 %	4591	100.0 %	16449	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life****Exhibit 18c. Quality of Life - EQ-5D Usual Activities**

The following table compares the EQ-5D Usual Activities domain between your site and STS InterMACS.

EQ-5D Usual Activities	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
I have no problems with performing my usual activities	24	16.4 %	43	26.0 %	14	19.7 %	81	21.2 %	1021	17.7 %	1109	18.2 %	1033	22.5 %	3163	19.2 %
I have some problems with performing my usual activities	72	49.3 %	73	44.2 %	30	42.2 %	175	45.8 %	2720	47.1 %	2961	48.5 %	2154	46.9 %	7835	47.6 %
I am unable to perform my usual activities	49	33.5 %	49	29.6 %	25	35.2 %	123	32.1 %	1940	33.6 %	1867	30.6 %	1228	26.7 %	5035	30.6 %
Unknown	1	0.6 %	.	.	2	2.8 %	3	0.7 %	84	1.4 %	156	2.5 %	176	3.8 %	416	2.5 %
TOTAL	146	100.0 %	165	100.0 %	71	100.0 %	382	100.0 %	5765	100.0 %	6093	100.0 %	4591	100.0 %	16449	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life****Exhibit 18d. Quality of Life - EQ-5D Pain/Discomfort**

The following table compares the EQ-5D Pain/Discomfort domain between your site and STS InterMACS.

EQ-5D Pain/Discomfort	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
I have no pain or discomfort	53	36.3 %	73	44.2 %	33	46.4 %	159	41.6 %	2439	42.3 %	2599	42.6 %	1943	42.3 %	6981	42.4 %
I have moderate pain or discomfort	72	49.3 %	77	46.6 %	29	40.8 %	178	46.5 %	2789	48.3 %	2864	47.0 %	2144	46.7 %	7797	47.4 %
I have extreme pain or discomfort	20	13.6 %	13	7.8 %	8	11.2 %	41	10.7 %	460	7.9 %	495	8.1 %	325	7.0 %	1280	7.7 %
Unknown	1	0.6 %	2	1.2 %	1	1.4 %	4	1.0 %	77	1.3 %	135	2.2 %	179	3.8 %	391	2.3 %
TOTAL	146	100.0 %	165	100.0 %	71	100.0 %	382	100.0 %	5765	100.0 %	6093	100.0 %	4591	100.0 %	16449	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life

Exhibit 18e. Quality of Life - EQ-5D Anxiety/Depression

The following table compares the EQ-5D Anxiety/Depression domain between your site and STS InterMACS.

EQ-5D Anxiety	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
I am not anxious or depressed	68	46.5 %	94	56.9 %	36	50.7 %	198	51.8 %	2627	45.5 %	2795	45.8 %	2115	46.0 %	7537	45.8 %
I am moderately anxious or depressed	63	43.1 %	63	38.1 %	32	45.0 %	158	41.3 %	2618	45.4 %	2683	44.0 %	1986	43.2 %	7287	44.3 %
I am extremely anxious or depressed	13	8.9 %	6	3.6 %	2	2.8 %	21	5.4 %	431	7.4 %	449	7.3 %	300	6.5 %	1180	7.1 %
Unknown	2	1.3 %	2	1.2 %	1	1.4 %	5	1.3 %	89	1.5 %	166	2.7 %	190	4.1 %	445	2.7 %
TOTAL	146	100.0 %	165	100.0 %	71	100.0 %	382	100.0 %	5765	100.0 %	6093	100.0 %	4591	100.0 %	16449	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life

Exhibit 18f. Quality of Life - EQ-5D Visual Analog Scale

The following table compares the EQ-5D Visual Analog Scale domain between your site and STS InterMACS.

GROUP=HOSPX-9999

EQ-5D - VAS Score		< 2014	2014 - 2017	2018 - 2021 (Jan-Jun)	TOTAL
	N	146	157	67	370
	Mean	39.07	49.64	44.06	44.46
	Std	28.02	26.47	24.51	27.11
	Min	0.00	0.00	0.00	0.00
	Max	100.00	100.00	92.00	100.00

GROUP=STS InterMACS

EQ-5D - VAS Score		< 2014	2014 - 2017	2018 - 2021 (Jan-Jun)	TOTAL
	N	5591	5818	4265	15674
	Mean	43.25	46.37	48.52	45.84
	Std	24.82	23.76	24.06	24.31
	Min	0.00	0.00	0.00	0.00
	Max	100.00	100.00	100.00	100.00

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life****Exhibit 18g. Quality of Life - EQ-5D Incomplete - Patient Reasons**

The following table compares the Patient Reasons the EQ-5D was not completed.

Patient Reasons for Incomplete EQ-5D	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Too sick (ex., intubated/sedated, critically ill, on short-term VAD)	53	56.9 %	67	52.3 %	58	35.8 %	178	46.4 %	2252	45.0 %	2524	47.2 %	1735	39.3 %	6511	44.1 %
Too tired	4	4.3 %	3	2.3 %	10	6.1 %	17	4.4 %	141	2.8 %	174	3.2 %	120	2.7 %	435	2.9 %
Too stressed, anxious, and/or depressed	.	.	11	8.5 %	1	0.6 %	12	3.1 %	159	3.1 %	251	4.6 %	193	4.3 %	603	4.0 %
No time / too busy	1	1.0 %	2	1.5 %	19	11.7 %	22	5.7 %	243	4.8 %	375	7.0 %	379	8.5 %	997	6.7 %
Too much trouble / don't want to be bothered / not interested	.	.	13	10.1 %	8	4.9 %	21	5.4 %	40	0.7 %	111	2.0 %	81	1.8 %	232	1.5 %
Can't concentrate	2	2.1 %	2	1.5 %	.	.	4	1.0 %	39	0.7 %	45	0.8 %	34	0.7 %	118	0.7 %
Unwilling to complete instrument, no reason given	1	1.0 %	12	9.3 %	9	5.5 %	22	5.7 %	60	1.1 %	162	3.0 %	115	2.6 %	337	2.2 %
Unable to read English and/or illiterate	3	3.2 %	.	.	2	1.2 %	5	1.3 %	42	0.8 %	61	1.1 %	40	0.9 %	143	0.9 %
Administrative (check specific reason below)	7	7.5 %	18	14.0 %	55	33.9 %	80	20.8 %	957	19.1 %	1638	30.6 %	1717	38.8 %	4312	29.2 %
Other/Unknown	22	23.6 %	22	5.7 %	1069	21.3 %	1069	7.2 %
TOTAL	93	100.0 %	128	100.0 %	162	100.0 %	383	100.0 %	5002	100.0 %	5341	100.0 %	4414	100.0 %	14757	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life****Exhibit 18h. Quality of Life - EQ-5D Incomplete - Administrative Reasons**

The following table compares the Administrative Reasons the EQ-5D was not completed.

Administrative Reasons for Incomplete EQ-5D	HOSPX-9999								STS InterMACS							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Urgent/emergent implant, no time to administer QOL instruments	.	.	5	26.3 %	5	9.0 %	10	11.6 %	30	2.2 %	137	8.3 %	117	6.8 %	284	6.0 %
Coordinator too busy or forgot to administer QOL instruments	7	58.3 %	9	47.3 %	48	87.2 %	64	74.4 %	479	35.3 %	866	52.7 %	913	53.1 %	2258	47.8 %
Unable to contact patient (ie., not hospitalized or no clinic visit) within the window for QOL instr	1	1.8 %	1	1.1 %	52	3.8 %	51	3.1 %	113	6.5 %	216	4.5 %
Other reason (describe)	5	41.6 %	5	26.3 %	1	1.8 %	11	12.7 %	793	58.5 %	589	35.8 %	574	33.4 %	1956	41.4 %
TOTAL	12	100.0 %	19	100.0 %	55	100.0 %	86	100.0 %	1354	100.0 %	1643	100.0 %	1717	100.0 %	4714	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life****Exhibit 19. Trailmaking**

Trailmaking Test time is the number of seconds required to complete the test.

GROUP=HOSPX-9999

Trailmaking Time(s)		< 2014	2014 - 2017	2018 - 2021 (Jan-Jun)	TOTAL
	N	116	104	35	255
	Mean	167.09	152.85	136.49	157.08
	Std	100.09	77.54	66.42	87.62
	Min	3.00	58.00	46.00	3.00
	Max	560.00	545.00	342.00	560.00

GROUP=STS Intermacs

Trailmaking Time(s)		< 2014	2014 - 2017	2018 - 2021 (Jan-Jun)	TOTAL
	N	4488	4165	2841	11494
	Mean	149.25	136.34	144.65	143.43
	Std	121.14	96.66	130.72	115.62
	Min	1.00	4.00	6.00	1.00
	Max	3600.00	3480.00	3600.00	3600.00

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.B. Implant Summaries****Exhibit 20. VAD Indication**

The following table summarizes additional implant reasons that necessitated the placement of a VAD at your site and STS InterMACS.

VAD INDICATION	HOSPX-9999		STS InterMACS	
	N	%	N	%
Failure to wean from Cardio Pulmonary Bypass	26	3.3 %	439	1.3 %
Persistent Heart Failure Following Cardiac Surgery	12	1.5 %	482	1.5 %
None	730	95.0 %	31093	97.1 %
Total Patients	768	100.0 %	32014	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.B. Implant Summaries

Exhibit 21. Device Type

The following tables summarizes the implant side (location) of VADs at your site and STS InterMACs over time.

Device Type	HOSPX-9999								STS InterMACs							
	< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL		< 2014		2014 - 2017		2018 - 2021 (Jan-Jun)		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
LVAD	227	93.8 %	288	95.6 %	251	95.4 %	766	95.0 %	10110	91.0 %	11191	93.7 %	10106	94.4 %	31407	93.0 %
RVAD	1	0.4 %	1	0.1 %	21	0.1 %	11	0.0 %	10	0.0 %	42	0.1 %
BIVAD	14	5.7 %	11	3.6 %	10	3.8 %	35	4.3 %	703	6.3 %	539	4.5 %	507	4.7 %	1749	5.1 %
TAH	.	.	2	0.6 %	2	0.7 %	4	0.4 %	266	2.3 %	202	1.6 %	75	0.7 %	543	1.6 %
TOTAL	242	100.0 %	301	100.0 %	263	100.0 %	806	100.0 %	11100	100.0 %	11943	100.0 %	10698	100.0 %	33741	100.0 %

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.B. Implant Summaries****Exhibit 22. Additional Interventions within 48 Hours of Implant**

This table lists the interventions that occurred during the 48 hours prior to implant. A patient can have more than 1 additional intervention.

ADDITIONAL INTERVENTIONS	HOSPX-9999			STS InterMACS		
	N	Yes	%	N	Yes	%
IABP	769	132	17.17%	32018	6373	19.90%
Dialysis	769	9	1.17%	32018	588	1.84%
Ultrafiltration	769	6	0.78%	32018	249	0.78%
Ventilator	769	41	5.33%	32018	2021	6.31%
Feeding Tube	769	6	0.78%	32018	577	1.80%
ECMO	769	15	1.95%	32018	1033	3.23%
None	769	598	77.76%	32018	22991	71.81%
CABG+	769	2	0.26%	32018	53	0.17%
Aortic Valve Replacement/Repair+	769	1	0.13%	32018	45	0.14%
Mitral Valve Replacement/Repair+	769	0	0.00%	32018	19	0.06%
Congenital Cardiac Surgery+	769	0	0.00%	32018	5	0.02%
LVAD+	769	1	0.13%	32018	580	1.81%
RVAD+	769	2	0.26%	32018	160	0.50%
TAH+	769	0	0.00%	32018	6	0.02%
Aneurysmectomy+	769	0	0.00%	32018	3	0.01%

Note: + = variable collected post relaunch (5/2/2012)

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Adverse Event Rates*****Exhibit 23a. Patient Percent Experiencing Each Adverse Event Type***

For each adverse event type, the percent of patients with a least one event of that type reported is presented at for your site and STS-INTERMACS overall.

Patient percent experiencing a specific adverse event = number of unique patients with reported event / number of patients at your site * 100

While useful, this measure does not take into consideration the varying amount of time on support for each patient (exposure time) or the timing of the adverse events. Subsequent exhibits use adverse event rates that more accurately compare adverse events reported at your site to the overall cohort.

	HOSPX-9999			STS Intermacs		
	Events	Patients	Patient Percent	Events	Patients	Patient Percent
Arterial Non-CNS Thromboembolism	6	6	0.7%	490	441	1.3%
Bleeding	400	226	28.0%	34548	14255	42.2%
Cardiac Arrhythmia	209	155	19.2%	16002	9609	28.5%
Device Malfunction and/or Pump Thrombosis	165	127	15.8%	13273	7989	23.7%
Hepatic Dysfunction	15	14	1.7%	1890	1712	5.1%
Infection	644	351	43.5%	39728	17445	51.7%
Myocardial Infarction	4	4	0.5%	229	206	0.6%
Neurological Dysfunction	219	173	21.5%	11916	8506	25.2%
Other Serious Adverse Event	230	130	16.1%	20799	10324	30.6%
Pericardial Drainage	20	18	2.2%	1602	1428	4.2%
Psychiatric Episode	19	14	1.7%	3264	2551	7.6%
Rehospitalization	2328	594	73.7%	121070	25055	74.3%
Renal Dysfunction	82	74	9.2%	6644	5509	16.3%
Respiratory Failure	142	110	13.6%	9912	7414	22.0%
Venous Thromboembolism	17	16	2.0%	1353	1247	3.7%
Wound Dehiscence	10	9	1.1%	625	557	1.7%

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Adverse Event Rates*****Exhibit 23b. Adverse Event Exposure***

The following table summarizes the total time patients receiving primary prospective implants have been followed at your site and STS InterMACS overall. The total follow-up time is divided into an early period (less than or equal to three months) and late period (more than three months). These totals are the accrued exposure time for each patient group and are used as the denominators in the following rate calculations.

Patient Follow-Up	HOSPX-9999	STS InterMACS
Patient exposure during the first 3 months post implant (months)	2156	91725
Patient exposure after the first 3 months post implant (months)	15313	686498
Number of Patients	806	33741

II.C. Post Implant Summary - Adverse Event Rates

Exhibit 23c. Adverse Event Rates

GROUP=HOSPX-9999

	HOSPX-9999					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
Arterial Non-CNS Thromboembolism	4	0.5%	0.19	2	0.2%	0.01
Bleeding	204	18.2%	9.46	196	14.6%	1.28
Cardiac Arrhythmia	120	13.2%	5.57	89	8.1%	0.58
Device Malfunction and/or Pump Thrombosis	32	3.3%	1.48	133	13.0%	0.87
Hepatic Dysfunction	10	1.1%	0.46	5	0.6%	0.03
Infection	202	19.4%	9.37	442	31.0%	2.89
Myocardial Infarction	3	0.4%	0.14	1	0.1%	0.01
Neurological Dysfunction	78	8.8%	3.62	141	14.1%	0.92
Other Serious Adverse Event	158	11.8%	7.33	72	5.8%	0.47
Pericardial Drainage	19	2.2%	0.88	1	0.1%	0.01
Psychiatric Episode	11	1.1%	0.51	8	0.7%	0.05
Rehospitalization	393	36.4%	18.23	1935	64.5%	12.64
Renal Dysfunction	60	6.8%	2.78	22	2.6%	0.14
Respiratory Failure	97	9.9%	4.50	45	4.7%	0.29
Venous Thromboembolism	14	1.6%	0.65	3	0.4%	0.02
Wound Dehiscence	10	1.1%	0.46	.	.	.

GROUP=STS InterMACS

	STS InterMACS					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
Arterial Non-CNS Thromboembolism	305	0.8%	0.33	185	0.5%	0.03
Bleeding	14585	26.8%	15.90	19963	25.0%	2.91
Cardiac Arrhythmia	8975	19.6%	9.78	7027	12.7%	1.02
Device Malfunction and/or Pump Thrombosis	2595	6.5%	2.83	10678	19.4%	1.56
Hepatic Dysfunction	929	2.6%	1.01	961	2.6%	0.14
Infection	13607	27.5%	14.83	26121	35.7%	3.80
Myocardial Infarction	88	0.3%	0.10	141	0.4%	0.02
Neurological Dysfunction	4193	10.8%	4.57	7723	16.4%	1.12
Other Serious Adverse Event	10447	19.2%	11.39	10352	16.7%	1.51
Pericardial Drainage	1540	4.1%	1.68	62	0.2%	0.01
Psychiatric Episode	1765	4.8%	1.92	1499	3.4%	0.22
Rehospitalization	18824	36.4%	20.52	102246	66.8%	14.89
Renal Dysfunction	3941	10.7%	4.30	2703	6.5%	0.39
Respiratory Failure	6927	16.5%	7.55	2985	7.2%	0.43
Venous Thromboembolism	1074	3.0%	1.17	279	0.8%	0.04
Wound Dehiscence	442	1.2%	0.48	183	0.5%	0.03

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Adverse Event Rates****Exhibit 23d. Infection Rates by Location**

The following table compares infection rates according to location at your site and STS InterMACS. Every infection location reported is counted in the table.

GROUP=HOSPX-9999

	HOSPX-9999					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
GI	12	1.4%	0.56	11	1.1%	0.07
Line Sepsis	9	1.1%	0.42	9	0.9%	0.06
Mediastinum	8	0.9%	0.37	1	0.1%	0.01
Other Specify	26	3.2%	1.21	52	5.5%	0.34
Peripheral Wound	2	0.2%	0.09	10	1.0%	0.07
Positive Blood Cultures	39	4.5%	1.81	72	6.9%	0.47
Pulmonary	57	6.5%	2.64	37	4.3%	0.24
Pump/Related - Drive Line	37	4.6%	1.72	237	18.9%	1.55
Pump/Related - Exit Cannula	2	0.2%	0.09	6	0.6%	0.04
Pump/Related - Pump Interior	1	0.1%	0.05	7	0.7%	0.05
Pump/Related - Pump Pocket	2	0.2%	0.09	7	0.9%	0.05
Unknown	4	0.5%	0.19	8	0.9%	0.05
Urinary Tract	38	4.2%	1.76	52	5.6%	0.34

GROUP=STS InterMACS

	STS InterMACS					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
GI	1063	2.9%	1.16	1311	3.3%	0.19
Line Sepsis	428	1.2%	0.47	562	1.5%	0.08
Mediastinum	591	1.6%	0.64	447	1.1%	0.07
Other Specify	1916	5.1%	2.09	3548	8.2%	0.52
Peripheral Wound	414	1.2%	0.45	670	1.7%	0.10
Positive Blood Cultures	2767	7.3%	3.02	7076	14.1%	1.03
Pulmonary	4167	10.5%	4.54	3467	7.9%	0.51
Pump/Related - Drive Line	1228	3.4%	1.34	9247	16.4%	1.35
Pump/Related - Exit Cannula	39	0.1%	0.04	216	0.6%	0.03
Pump/Related - Pump Interior	39	0.1%	0.04	136	0.4%	0.02
Pump/Related - Pump Pocket	354	1.0%	0.39	900	2.2%	0.13
Unknown	410	1.1%	0.45	525	1.4%	0.08
Urinary Tract	2541	6.6%	2.77	3270	6.8%	0.48

II.C. Post Implant Summary - Adverse Event Rates

Exhibit 23e. Bleeding Rates by Source

The following table compares bleeding rates according to source at your site and STS InterMACS. Every bleed source reported is counted in the table.

NOTE: These rates are reported for patients receiving a implant starting in March 2009.

GROUP=HOSPX-9999

	HOSPX-9999					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
Device anastomosis	1	0.1%	0.05	.	.	.
ENT / Dental	9	0.9%	0.43	23	1.5%	0.16
GI OVERALL: upper, lower, unknown	79	8.5%	3.80	137	11.7%	0.92
GI: Lower gastrointestinal (colon, rectum, and anus)	23	2.6%	1.11	32	3.6%	0.22
GI: Upper gastrointestinal (esophagus, stomach, duod)	42	4.9%	2.02	57	5.7%	0.38
GI: unknown, but guaiac positive stools	17	2.1%	0.82	52	5.8%	0.35
Intra-abdominal	3	0.4%	0.14	2	0.3%	0.01
Mediastinal: Unspecified	20	2.2%	0.96	.	.	.
Mediastinal: chest wall	5	0.6%	0.24	1	0.1%	0.01
Mediastinal: coagulopathy with no surgical site	4	0.5%	0.19	.	.	.
Mediastinal: inflow conduit	1	0.1%	0.05	.	.	.
Mediastinal: other surgical site	2	0.3%	0.10	.	.	.
Mediastinal: outflow-aorta anastomosis	2	0.3%	0.10	.	.	.
Other	40	4.8%	1.93	22	2.2%	0.15
Pleural space	9	1.2%	0.43	1	0.1%	0.01
Pulmonary	1	0.1%	0.05	4	0.4%	0.03
Pump Pocket	8	0.9%	0.39	1	0.1%	0.01
Retroperitoneal	4	0.5%	0.19	2	0.3%	0.01
Urinary tract	4	0.5%	0.19	4	0.5%	0.03

GROUP=STS InterMACS

	STS InterMACS					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
Device anastomosis	113	0.3%	0.13	105	0.2%	0.02
ENT / Dental	595	1.6%	0.67	1204	2.5%	0.18
GI OVERALL: upper, lower, unknown	5775	12.5%	6.54	13768	18.8%	2.06
GI: Lower gastrointestinal (colon, rectum, and anus)	1716	4.3%	1.94	3367	7.0%	0.50
GI: Upper gastrointestinal (esophagus, stomach, duod)	2912	6.8%	3.30	6954	11.7%	1.04
GI: unknown, but guaiac positive stools	1486	3.9%	1.68	4008	7.5%	0.60
Intra-abdominal	171	0.5%	0.19	276	0.8%	0.04
Mediastinal: Unspecified	1779	4.7%	2.01	92	0.2%	0.01
Mediastinal: aortic-venous cannulation site	34	0.1%	0.04	2	0.0%	0.00
Mediastinal: chest wall	1059	3.0%	1.20	88	0.3%	0.01
Mediastinal: coagulopathy with no surgical site	287	0.8%	0.32	14	0.0%	0.00
Mediastinal: inflow conduit	38	0.1%	0.04	5	0.0%	0.00
Mediastinal: other surgical site	349	1.0%	0.40	59	0.2%	0.01
Mediastinal: outflow conduit	73	0.2%	0.08	18	0.1%	0.00

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Adverse Event Rates****Exhibit 23e. Bleeding Rates by Source**

GROUP=STS Intermacs

	STS Intermacs					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
Mediastinal: outflow-aorta anastomosis	117	0.3%	0.13	11	0.0%	0.00
Other	2936	7.0%	3.32	3715	8.4%	0.56
Pleural space	656	1.8%	0.74	65	0.2%	0.01
Pulmonary	291	0.8%	0.33	134	0.3%	0.02
Pump Pocket	276	0.8%	0.31	76	0.2%	0.01
Retroperitoneal	134	0.4%	0.15	150	0.4%	0.02
Urinary tract	179	0.5%	0.20	319	0.8%	0.05

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Adverse Event Rates*****Exhibit 23f. Device Malfunction and/or Pump Thrombosis by type***

The following table compares Device Malfunction and/or Pump Thrombosis rates according to type at your site and STS InterMACS.

NOTE: These rates are reported for patients receiving implant starting with Version 4.0 (June 2, 2014).

GROUP=HOSPX-9999

	HOSPX-9999					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
Device Malfunction	5	0.7%	0.35	29	4.6%	0.32
Pump Thrombosis	13	1.9%	0.91	45	6.3%	0.50

GROUP=STS InterMACS

	STS InterMACS					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
Device Malfunction	636	2.6%	1.09	2516	8.4%	0.65
Pump Thrombosis	853	3.4%	1.46	2494	8.6%	0.65

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Adverse Event Rates*****Exhibit 23g. Neurological Dysfunction by Category***

The following table compares neurological dysfunction rates according to category at your site and STS InterMACS.

NOTE: These rates are reported for patients receiving implant starting with Version 3.0 (May 2, 2012).


GROUP=HOSPX-9999

	HOSPX-9999					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
CVA	37	4.3%	2.06	64	7.4%	0.52
Confusion	4	0.5%	0.22	13	1.4%	0.11
Encephalopathy	7	0.9%	0.39	9	1.0%	0.07
Seizure	13	1.6%	0.73	6	0.5%	0.05
TIA	3	0.4%	0.17	17	1.9%	0.14

GROUP=STS InterMACS


	STS InterMACS					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
CVA	2021	5.4%	2.73	3884	9.2%	0.73
Confusion	262	0.7%	0.35	516	1.3%	0.10
Encephalopathy	464	1.3%	0.63	434	1.1%	0.08
Seizure	266	0.8%	0.36	332	0.8%	0.06
TIA	326	0.9%	0.44	785	2.0%	0.15
Unspecified	.	.	.	1	0.0%	0.00

Exhibit 24a. Time to First Device Malfunction / Thrombus




Months after Device Implant	STS Intermacs	HOSPX-9999
1	97.2% (97.1%-97.3%)	98.5% (97.9%-98.8%)
3	93.7% (93.6%-93.9%)	96.8% (96.1%-97.4%)
6	90.5% (90.4%-90.7%)	94.1% (93.1%-94.9%)
9	87.6% (87.4%-87.8%)	91.7% (90.5%-92.7%)
12	84.7% (84.5%-85.0%)	88.7% (87.3%-89.9%)
24	74.0% (73.7%-74.3%)	81.8% (80.0%-83.6%)
36	63.8% (63.4%-64.2%)	74.3% (71.7%-76.6%)
48	54.8% (54.3%-55.3%)	67.8% (64.7%-70.8%)
60	47.8% (47.2%-48.4%)	62.7% (59.0%-66.2%)

Exhibit 24b. Time to First Infection



Months after Device Implant	STS Intermacs	HOSPX-9999
1	81.9% (81.7%-82.1%)	88.5% (87.4%-89.6%)
3	73.0% (72.7%-73.2%)	80.7% (79.2%-82.1%)
6	65.6% (65.3%-65.9%)	72.6% (70.9%-74.3%)
9	60.0% (59.7%-60.3%)	66.5% (64.6%-68.3%)
12	54.9% (54.6%-55.2%)	59.9% (57.9%-61.9%)
24	42.3% (42.0%-42.6%)	48.2% (46.0%-50.5%)
36	33.9% (33.5%-34.2%)	39.5% (36.9%-42.1%)
48	27.5% (27.1%-27.9%)	31.4% (28.5%-34.3%)
60	22.7% (22.3%-23.2%)	27.6% (24.6%-30.6%)

Exhibit 24c. Time to First Neurological Dysfunction



Months after Device Implant	STS Intermacs	HOSPX-9999
1	93.1% (93.0%-93.2%)	94.0% (93.1%-94.8%)
3	89.5% (89.3%-89.7%)	90.8% (89.7%-91.8%)
6	86.1% (85.9%-86.3%)	86.6% (85.3%-87.8%)
9	83.2% (83.0%-83.5%)	83.7% (82.2%-85.0%)
12	80.7% (80.5%-80.9%)	82.3% (80.7%-83.7%)
24	72.9% (72.6%-73.2%)	76.0% (74.1%-77.8%)
36	66.3% (66.0%-66.7%)	70.5% (68.2%-72.7%)
48	60.8% (60.4%-61.3%)	67.1% (64.4%-69.7%)
60	55.8% (55.3%-56.3%)	64.3% (61.2%-67.2%)

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 25. Hospital Days for Discharged Patients

This table compares hospital days (initial hospitalization) from implant date to discharge date for patients with submitted discharge forms. For most patients this is the date they were discharged alive on a device but for patients that died or were transplanted in the implantation hospitalization it is the death date or transplant date, respectively. The first section (All) compares overall hospital days. The remaining sections compare hospital days by each device type, LVAD, Bi-VAD and TAH respectively.

HOSPITAL DAYS FOR DISCHARGED PATIENTS			HOSPX-9999				STS Intermacs			
			< 2014	2014 - 2017	2018 - 2021 (Jan-Jun)	TOTAL	< 2014	2014 - 2017	2018 - 2021 (Jan-Jun)	TOTAL
All		N	215	265	215	695	9658	10367	9250	29275
		Mean	28.25	25.23	28.48	27.17	27.59	25.64	26.79	26.65
		Std	48.22	19.77	23.57	32.24	33.14	26.23	28.19	29.29
		Median	18	18	21	19	20	19	20	20
		Min	8	0	8	0	0	0	0	0
		Max	581	154	179	581	1492	1131	916	1492
BiVAD		N	6	8	6	20	395	299	316	1010
		Mean	60.33	44.25	64.83	55.25	55.07	47.31	48.19	50.62
		Std	32.14	34.26	57.13	40.63	42.57	38.16	44.33	42.00
		Median	49	36	44	44	44	37	38	40
		Min	32	0	29	0	0	0	0	0
		Max	113	98	179	179	400	433	396	433
LVAD		N	209	257	208	674	9162	9988	8902	28052
		Mean	27.33	24.64	27.10	26.23	25.51	24.70	25.91	25.35
		Std	48.35	18.95	20.78	31.52	28.04	25.09	26.92	26.67
		Median	18	18	21	19	20	19	20	19
		Min	8	7	8	7	0	0	0	0
		Max	581	154	141	581	1492	1131	916	1492
RVAD		N	14	7	3	24
		Mean	56.43	34.14	22.00	45.63
		Std	42.04	33.22	18.03	38.72
		Median	48	22	17	32
		Min	8	13	7	7
		Max	156	106	42	156
TAH		N	.	.	1	1	87	73	29	189
		Mean	.	.	98.00	98.00	117.43	65.05	61.86	88.67
		Std	136.84	44.92	57.95	102.71
		Median	.	.	98	98	76	51	54	58
		Min	.	.	98	98	25	14	16	14
		Max	.	.	98	98	916	212	331	916

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - 30 Day Readmission

Exhibit 26. 30 Days Readmission

The following tables present the counts and percentages of patients that were discharged alive on a device that were readmitted within 30 days for your site and for STS Intermacs overall. Percentages are listed by device type and discharge year.

GROUP=HOSPX-9999

30 Day Readmission		Device Type						TOTAL		
		LVAD			BiVAD					
		Patients Discharged Alive on Device (n)	Patients with 30 day Readmission	% With 30 day Readmission	Patients Discharged Alive on Device (n)	Patients with 30 day Readmission	% With 30 day Readmission	Patients Discharged Alive on Device (n)	Patients with 30 day Readmission	% With 30 day Readmission
Discharge Year										
	2006	2	0	0.0%	.	.	.	2	0	0.0%
	2007	3	1	33.3%	.	.	.	3	1	33.3%
	2008	16	4	25.0%	.	.	.	16	4	25.0%
	2009	21	2	9.5%	1	0	0.0%	22	2	9.1%
	2010	27	7	25.9%	2	1	50.0%	29	8	27.6%
	2011	29	10	34.5%	2	2	100.0%	31	12	38.7%
	2012	44	13	29.5%	1	1	100.0%	45	14	31.1%
	2013	62	19	30.6%	.	.	.	62	19	30.6%
	2014	58	17	29.3%	2	1	50.0%	60	18	30.0%
	2015	84	19	22.6%	.	.	.	84	19	22.6%
	2016	80	22	27.5%	3	1	33.3%	83	23	27.7%
	2017	34	11	32.4%	3	0	0.0%	37	11	29.7%
	2018	65	15	23.1%	1	1	100.0%	66	16	24.2%
	2019	85	18	21.2%	4	2	50.0%	89	20	22.5%
	2020	49	12	24.5%	.	.	.	49	12	24.5%
	2021	13	4	30.8%	1	0	0.0%	14	4	28.6%
TOTAL		672	174	25.9%	20	9	45.0%	692	183	26.4%

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - 30 Day Readmission

Exhibit 26. 30 Days Readmission

GROUP=STS Intermacs

30 Day Readmission		Device Type								
		LVAD			RVAD			BiVAD		
		Patients Discharged Alive on Device (n)	Patients with 30 day Readmission	% With 30 day Readmission	Patients Discharged Alive on Device (n)	Patients with 30 day Readmission	% With 30 day Readmission	Patients Discharged Alive on Device (n)	Patients with 30 day Readmission	% With 30 day Readmission
Discharge Year										
	2006	60	17	28.3%	.	.	.	5	2	40.0%
	2007	188	46	24.5%	4	2	50.0%	31	11	35.5%
	2008	540	136	25.2%	.	.	.	42	15	35.7%
	2009	795	185	23.3%	.	.	.	52	16	30.8%
	2010	1415	357	25.2%	2	0	0.0%	68	19	27.9%
	2011	1666	472	28.3%	1	1	100.0%	61	17	27.9%
	2012	1999	567	28.4%	2	1	50.0%	53	16	30.2%
	2013	2389	769	32.2%	3	0	0.0%	63	16	25.4%
	2014	2417	694	28.7%	2	1	50.0%	83	21	25.3%
	2015	2694	804	29.8%	4	3	75.0%	69	23	33.3%
	2016	2552	725	28.4%	.	.	.	72	18	25.0%
	2017	2188	651	29.8%	.	.	.	62	23	37.1%
	2018	2612	722	27.6%	.	.	.	85	19	22.4%
	2019	2900	753	26.0%	.	.	.	96	36	37.5%
	2020	2453	595	24.3%	1	0	0.0%	92	25	27.2%
	2021	1053	237	22.5%	.	.	.	51	11	21.6%
	TOTAL	27921	7730	27.7%	19	8	42.1%	985	288	29.2%

30 Day Readmission		Device Type			TOTAL		
		TAH					
		Patients Discharged Alive on Device (n)	Patients with 30 day Readmission	% With 30 day Readmission	Patients Discharged Alive on Device (n)	Patients with 30 day Readmission	% With 30 day Readmission
Discharge Year							
	2006	.	.	.	65	19	29.2%
	2007	3	0	0.0%	226	59	26.1%
	2008	1	0	0.0%	583	151	25.9%
	2009	.	.	.	847	201	23.7%
	2010	2	1	50.0%	1487	377	25.4%
	2011	14	3	21.4%	1742	493	28.3%
	2012	16	6	37.5%	2070	590	28.5%
	2013	16	4	25.0%	2471	789	31.9%
	2014	23	10	43.5%	2525	726	28.8%
	2015	18	6	33.3%	2785	836	30.0%
	2016	17	8	47.1%	2641	751	28.4%
	2017	16	7	43.8%	2266	681	30.1%
	2018	8	4	50.0%	2705	745	27.5%
	2019	14	4	28.6%	3010	793	26.3%
	2020	5	4	80.0%	2551	624	24.5%
	2021	2	1	50.0%	1106	249	22.5%
TOTAL	155	58	37.4%	29080	8084	27.8%	

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Functional Capacity****Exhibit 27a. 6 Minute Walk - Overall**

The following tables summarize Six Minute Walk completion status and values at your site and STS InterMACs at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS												
		Not Done: Other/Unknown		Not Done: Too Sick		Outlier		Complete						
		N	%	N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	806	329	40.8	337	41.8	.	.	140	17.4	759.1	333.0	750.0	0.0	1500.0
3 Month	614	301	49.0	52	8.5	1	0.2	260	42.3	949.0	369.7	1000.0	42.0	1850.0
6 Month	528	374	70.8	21	4.0	3	0.6	130	24.6	974.6	360.1	1020.0	50.0	2130.0
1 Year	391	297	76.0	11	2.8	.	.	83	21.2	1013.6	322.6	1050.0	335.0	1620.0
2 Year	220	171	77.7	4	1.8	.	.	45	20.5	996.8	363.6	1000.0	200.0	1700.0
3 Year	106	98	92.5	3	2.8	.	.	5	4.7	1216.0	255.9	1200.0	840.0	1500.0
4 Year	71	65	91.5	6	8.5	1022.8	223.9	1057.5	672.0	1300.0
5 Year	31	25	80.6	3	9.7	.	.	3	9.7	898.3	517.5	900.0	380.0	1415.0


GROUP=STS InterMACs

VISIT	Patients (n)	COMPLETION STATUS								Six Minute Walk (ft)				
		Not Done: Other/Unknown		Not Done: Too Sick		Outlier		Complete						
	N	N	%	N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	33741	11552	34.2	16112	47.8	15	0.0	6062	18.0	799.9	374.9	800.0	0.0	2388.0
3 Month	27048	15419	57.0	2666	9.9	20	0.1	8943	33.1	1033.3	369.0	1060.0	1.0	2400.0
6 Month	23486	13148	56.0	1749	7.4	38	0.2	8551	36.4	1100.2	375.2	1131.0	1.0	2400.0
1 Year	17258	9917	57.5	1144	6.6	20	0.1	6177	35.8	1111.5	378.7	1150.0	1.0	2400.0
2 Year	9794	5869	59.9	693	7.1	8	0.1	3224	32.9	1096.3	373.5	1130.0	14.0	2400.0
3 Year	5539	3481	62.8	419	7.6	2	0.0	1637	29.6	1092.1	372.5	1106.0	15.0	2359.0
4 Year	3244	2124	65.5	257	7.9	2	0.1	861	26.5	1068.0	379.7	1100.0	5.0	2320.0
5 Year	1915	1277	66.7	151	7.9	3	0.2	484	25.3	1030.2	404.6	1068.0	0.0	2145.0

II.C. Post Implant Summary - Functional Capacity

Exhibit 27a. 6 Minute Walk - Overall

The following figure summarize Six Minute Walk - Overall values your site and STS Intermacs at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Functional Capacity****Exhibit 27b. 6 Minute Walk - LVAD**

The following tables summarize Six Minute Walk completion status and values at your site and STS InterMACs at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS												
		Not Done: Other/Unknown		Not Done: Too Sick		Outlier		Complete						
		N	%	N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	766	316	41.3	310	40.5	.	.	140	18.3	759.1	333.0	750.0	0.0	1500.0
3 Month	590	290	49.2	46	7.8	1	0.2	253	42.9	956.9	366.1	1000.0	42.0	1850.0
6 Month	511	368	72.0	18	3.5	3	0.6	122	23.9	986.1	352.3	1034.5	80.0	2130.0
1 Year	376	289	76.9	10	2.7	.	.	77	20.5	1018.9	311.4	1060.0	335.0	1620.0
2 Year	212	168	79.2	4	1.9	.	.	40	18.9	1017.0	331.4	1007.5	200.0	1700.0
3 Year	105	97	92.4	3	2.9	.	.	5	4.8	1216.0	255.9	1200.0	840.0	1500.0
4 Year	70	64	91.4	6	8.6	1022.8	223.9	1057.5	672.0	1300.0
5 Year	30	24	80.0	3	10.0	.	.	3	10.0	898.3	517.5	900.0	380.0	1415.0


GROUP=STS InterMACs

VISIT	Patients (n)	COMPLETION STATUS								Six Minute Walk (ft)				
		Not Done: Other/Unknown		Not Done: Too Sick		Outlier		Complete						
	N	N	%	N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	31407	11084	35.3	14421	45.9	15	0.0	5887	18.7	801.7	374.8	800.0	0.0	2388.0
3 Month	25727	14729	57.3	2362	9.2	17	0.1	8619	33.5	1037.4	368.3	1067.0	1.0	2400.0
6 Month	22588	12675	56.1	1619	7.2	38	0.2	8256	36.6	1103.2	374.1	1135.0	1.0	2400.0
1 Year	16700	9587	57.4	1106	6.6	20	0.1	5987	35.9	1112.0	378.9	1150.0	1.0	2400.0
2 Year	9555	5724	59.9	673	7.0	8	0.1	3150	33.0	1097.0	373.9	1130.0	14.0	2400.0
3 Year	5421	3407	62.8	413	7.6	2	0.0	1599	29.5	1092.9	370.9	1108.0	15.0	2359.0
4 Year	3186	2089	65.6	255	8.0	2	0.1	840	26.4	1066.8	379.8	1100.0	5.0	2320.0
5 Year	1874	1253	66.9	149	8.0	3	0.2	469	25.0	1030.5	406.2	1066.0	0.0	2145.0

II.C. Post Implant Summary - Functional Capacity

Exhibit 27b. 6 Minute Walk - LVAD

The following figure summarize Six Minute Walk - LVAD values your site and STS Intermacs at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Functional Capacity****Exhibit 27c. 6 Minute Walk - BiVAD**

The following tables summarize Six Minute Walk completion status and values at your site and STS InterMACs at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS										
		Not Done: Other/Unknown		Not Done: Too Sick		Complete						
		N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	35	12	34.3	23	65.7
3 Month	21	10	47.6	4	19.0	7	33.3	662.7	416.3	825.0	175.0	1103.0
6 Month	16	6	37.5	2	12.5	8	50.0	798.8	453.5	875.0	50.0	1450.0
1 Year	15	8	53.3	1	6.7	6	40.0	945.5	475.8	907.5	373.0	1600.0
2 Year	8	3	37.5	.	.	5	62.5	835.0	588.9	825.0	200.0	1450.0
3 Year	1	1	100.0
4 Year	1	1	100.0
5 Year	1	1	100.0


GROUP=STS InterMACs

VISIT	Patients (n)	COMPLETION STATUS												
		Not Done: Other/Unknown		Not Done: Too Sick		Outlier		Complete		Six Minute Walk (ft)				
		N	%	N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	1749	382	21.8	1237	70.7	.	.	130	7.4	706.6	357.0	671.0	100.0	1800.0
3 Month	988	538	54.5	216	21.9	2	0.2	232	23.5	902.7	362.9	912.5	15.0	2283.0
6 Month	722	387	53.6	105	14.5	.	.	230	31.9	991.6	398.6	1050.0	3.0	1871.0
1 Year	477	290	60.8	33	6.9	.	.	154	32.3	1074.0	373.7	1090.0	15.0	1951.0
2 Year	220	134	60.9	18	8.2	.	.	68	30.9	1064.0	368.5	1091.0	150.0	1738.0
3 Year	110	68	61.8	5	4.5	.	.	37	33.6	1058.2	443.0	1043.0	220.0	1774.0
4 Year	54	31	57.4	2	3.7	.	.	21	38.9	1115.0	383.2	1176.0	370.0	1721.0
5 Year	40	23	57.5	2	5.0	.	.	15	37.5	1019.7	361.4	1087.0	336.0	1570.0

II.C. Post Implant Summary - Functional Capacity

Exhibit 27c. 6 Minute Walk - BiVAD

The following figure summarize Six Minute Walk - BiVAD values your site and STS Intermacs at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



II.C. Post Implant Summary - Functional Capacity

Exhibit 27d. 6 Minute Walk - TAH

The following tables summarize Six Minute Walk completion status and values at your site and STS Intermacs at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS								
		Not Done: Too Sick		Not Done: Other/Unknown						
		N	N	%	N	%	Mean	Std	Median	Min
Pre-Implant	4	3	75.0	1	25.0
3 Month	2	1	50.0	1	50.0


GROUP=STS Intermacs

[illegible]

II.C. Post Implant Summary - Functional Capacity

Exhibit 27d. 6 Minute Walk - TAH

The following figure summarize Six Minute Walk - TAH values your site and STS Intermacs at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Functional Capacity****Exhibit 28. VO2 Max**

The following tables summarize VO2 Max completion status and values at your site and STS InterMACs at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS											
		Not Done: Other/Unknown		Not Done: Too Sick		Complete							
		N	%	N	%	N	%	Mean	Std	Median	Min	Max	
Pre-Implant	806	554	68.7	235	29.2	17	2.1	11.8	6.6	10.5	4.0	35.0	
3 Month	614	580	94.5	32	5.2	2	0.3	12.0	2.8	12.0	10.0	14.0	
6 Month	528	507	96.0	19	3.6	2	0.4	10.5	2.1	10.5	9.0	12.0	
1 Year	391	382	97.7	8	2.0	1	0.3	9.0	.	9.0	9.0	9.0	
2 Year	220	217	98.6	3	1.4	
3 Year	106	104	98.1	2	1.9	
4 Year	71	71	100.0	
5 Year	31	29	93.5	2	6.5	


GROUP=STS InterMACs

VISIT	Patients (n)	COMPLETION STATUS								VO2 Max (mL/kg/min)					
		Not Done: Other/Unknown		Not Done: Too Sick		Outlier		Complete							
	N	N	%	N	%	N	%	N	%	Mean	Std	Median	Min	Max	
Pre-Implant	33741	17696	52.4	13205	39.1	35	0.1	2805	8.3	11.5	5.0	11.0	0.0	73.0	
3 Month	27048	24854	91.9	1943	7.2	32	0.1	219	0.8	13.1	4.8	13.0	1.1	43.0	
6 Month	23486	21999	93.7	1208	5.1	29	0.1	250	1.1	13.8	6.1	13.0	1.0	63.0	
1 Year	17258	16349	94.7	745	4.3	22	0.1	142	0.8	13.4	6.1	13.0	1.0	53.0	
2 Year	9794	9314	95.1	406	4.1	7	0.1	67	0.7	15.0	9.4	13.0	0.8	58.0	
3 Year	5539	5292	95.5	223	4.0	5	0.1	19	0.3	12.1	4.8	11.2	5.7	24.5	
4 Year	3244	3108	95.8	120	3.7	5	0.2	11	0.3	9.5	4.7	10.2	0.9	17.0	
5 Year	1915	1829	95.5	76	4.0	3	0.2	7	0.4	10.2	5.2	11.6	0.0	17.0	

II.C. Post Implant Summary - Functional Capacity

Exhibit 28. VO2 Max

The following figure summarize VO2 Max values your site and STS Intermacs at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Functional Capacity****Exhibit 29. Peak R**

The following tables summarize Peak R completion status and values at your site and STS InterMACs at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS						Peak R (%)				
		Not Done: Other/Unknown		Outlier		Complete						
		N	N	%	N	%	N	%	Mean	Std	Median	Min
Pre-Implant	806	792	98.3	3	0.4	11	1.4	1.1	0.1	1.1	1.0	1.3
3 Month	614	613	99.8	.	.	1	0.2	1.1	.	1.1	1.1	1.1
6 Month	528	526	99.6	.	.	2	0.4	1.2	0.0	1.2	1.2	1.2
1 Year	391	391	100.0
2 Year	220	220	100.0
3 Year	106	106	100.0
4 Year	71	71	100.0
5 Year	31	31	100.0


GROUP=STS InterMACs

VISIT	Patients (n)	COMPLETION STATUS						Peak R (%)					
		Not Done: Other/Unknown		Outlier		Complete							
		N	N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	33741	32011	94.9	197	0.6	1533	4.5	1.1	0.2	1.1	0.7	3.4	
3 Month	27048	26888	99.4	10	0.0	150	0.6	1.1	0.1	1.1	0.8	1.4	
6 Month	23486	23300	99.2	12	0.1	174	0.7	1.1	0.1	1.1	0.2	1.5	
1 Year	17258	17143	99.3	9	0.1	106	0.6	1.1	0.2	1.1	0.0	1.4	
2 Year	9794	9738	99.4	7	0.1	49	0.5	1.1	0.1	1.1	0.8	1.5	
3 Year	5539	5521	99.7	1	0.0	17	0.3	1.1	0.1	1.1	0.9	1.4	
4 Year	3244	3237	99.8	.	.	7	0.2	1.1	0.1	1.1	1.0	1.2	
5 Year	1915	1908	99.6	.	.	7	0.4	0.9	0.4	1.1	0.0	1.2	

II.C. Post Implant Summary - Functional Capacity

Exhibit 29. Peak R

The following figure summarize Peak R values your site and STS Intermacs at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Functional Capacity****Exhibit 30. Gait Speed**

The following tables summarize Gait Speed completion status and values at your site and STS InterMACs at select follow-up visits. Only follow-up data for patients first devices are considered for this summary.

Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS						Gait Speed (Feet/Sec) - DV					
		Not Done: Other/Unknown		Not Done: Too Sick		Complete							
	N	N	%	N	%	N	%	Mean	Std	Median	Min	Max	
Pre-Implant	806	575	71.3	206	25.6	25	3.1	2.0	0.6	2.1	0.7	3.0	
3 Month	614	494	80.5	40	6.5	80	13.0	3.8	1.5	3.8	1.0	7.9	
6 Month	528	436	82.6	16	3.0	76	14.4	3.9	1.6	3.8	1.5	9.9	
1 Year	391	330	84.4	11	2.8	50	12.8	4.1	1.4	4.0	1.5	8.0	
2 Year	220	181	82.3	5	2.3	34	15.5	4.0	1.4	4.1	0.8	6.8	
3 Year	106	100	94.3	2	1.9	4	3.8	3.8	2.3	2.8	2.5	7.1	
4 Year	71	64	90.1	1	1.4	6	8.5	3.5	0.8	3.4	2.5	4.8	
5 Year	31	24	77.4	3	9.7	4	12.9	3.1	1.1	3.4	1.5	3.8	


GROUP=STS InterMACs

VISIT	Patients (n)	COMPLETION STATUS								Gait Speed (Feet/Sec) - DV					
		Not Done: Other/Unknown		Not Done: Too Sick		Outlier		Complete							
	N	N	%	N	%	N	%	N	%	Mean	Std	Median	Min	Max	
Pre-Implant	33741	19727	58.5	11833	35.1	32	0.1	2149	6.4	2.6	1.3	2.5	0.0	10.0	
3 Month	27048	20288	75.0	2113	7.8	20	0.1	4627	17.1	3.3	1.3	3.2	0.0	10.0	
6 Month	23486	17514	74.6	1393	5.9	15	0.1	4564	19.4	3.5	1.4	3.5	0.0	10.0	
1 Year	17258	12850	74.5	937	5.4	15	0.1	3456	20.0	3.6	1.4	3.6	0.0	10.0	
2 Year	9794	7217	73.7	612	6.2	14	0.1	1951	19.9	3.6	1.3	3.5	0.0	9.6	
3 Year	5539	4131	74.6	374	6.8	4	0.1	1030	18.6	3.5	1.3	3.5	0.0	9.4	
4 Year	3244	2461	75.9	224	6.9	2	0.1	557	17.2	3.5	1.2	3.5	0.0	8.3	
5 Year	1915	1489	77.8	131	6.8	2	0.1	293	15.3	3.4	1.1	3.3	0.3	8.3	

II.C. Post Implant Summary - Functional Capacity

Exhibit 30. Gait Speed

The following figure summarize Gait Speed values your site and STS InterMACS at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Functional Capacity****Exhibit 31. Trailmaking**

The following tables summarize Trailmaking completion status and values at your site and STS InterMACS at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS				Trailmaking Time (sec)				
		Incomplete		Complete						
	N	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	806	551	68.4	255	31.6	157.1	87.6	133.0	3.0	560.0
3 Month	614	259	42.2	355	57.8	140.1	99.9	117.0	30.0	840.0
6 Month	528	230	43.6	298	56.4	128.7	77.2	111.5	30.0	640.0
1 Year	391	184	47.1	207	52.9	119.7	66.1	109.0	25.0	417.0
2 Year	220	100	45.5	120	54.5	121.2	81.6	103.0	42.0	584.0
3 Year	106	57	53.8	49	46.2	135.0	87.5	109.0	36.0	506.0
4 Year	71	52	73.2	19	26.8	115.0	50.7	110.0	43.0	250.0
5 Year	31	21	67.7	10	32.3	101.4	40.8	91.0	57.0	169.0


GROUP=STS InterMACS

VISIT	Patients (n)	COMPLETION STATUS				Trailmaking Time (sec)				
		Incomplete		Complete						
	N	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	33741	22247	65.9	11494	34.1	143.4	115.6	120.0	1.0	3600.0
3 Month	27048	16421	60.7	10627	39.3	118.6	90.0	100.0	1.0	3479.0
6 Month	23486	13530	57.6	9956	42.4	112.6	69.8	95.0	1.0	1360.0
1 Year	17258	9944	57.6	7314	42.4	113.1	75.8	95.0	5.0	2134.0
2 Year	9794	5908	60.3	3886	39.7	112.1	66.0	96.0	2.0	919.0
3 Year	5539	3520	63.5	2019	36.5	114.7	70.6	97.0	1.0	960.0
4 Year	3244	2170	66.9	1074	33.1	113.9	82.4	96.0	3.0	1848.0
5 Year	1915	1334	69.7	581	30.3	113.8	69.6	96.0	20.0	680.0

II.C. Post Implant Summary - Functional Capacity

Exhibit 31. Trailmaking

The following figure summarize Trailmaking values your site and STS InterMACS at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Functional Capacity****Exhibit 32. NYHA Class**

The following tables summarize NYHA completion status and values at your site and STS InterMACs at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS				NYHA Class				
		Not Done: Other/Unknown		Complete						
	N	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	806	53	6.6	753	93.4	3.8	0.4	4.0	1.0	4.0
3 Month	614	69	11.2	545	88.8	2.2	1.0	2.0	1.0	4.0
6 Month	528	67	12.7	461	87.3	2.0	0.9	2.0	1.0	4.0
1 Year	391	47	12.0	344	88.0	1.8	0.8	2.0	1.0	4.0
2 Year	220	31	14.1	189	85.9	1.8	0.8	2.0	1.0	4.0
3 Year	106	9	8.5	97	91.5	1.9	0.8	2.0	1.0	4.0
4 Year	71	8	11.3	63	88.7	1.9	0.8	2.0	1.0	4.0
5 Year	31	2	6.5	29	93.5	2.0	0.9	2.0	1.0	4.0


GROUP=STS InterMACs

VISIT	Patients (n)	COMPLETION STATUS				NYHA Class					
		Not Done: Other/Unknown		Complete							
	N	N	%	N	%	Mean	Std	Median	Min	Max	
Pre-Implant	33741	2663	7.9	31078	92.1	3.8	0.4	4.0	1.0	4.0	
3 Month	27048	5132	19.0	21916	81.0	2.2	0.8	2.0	1.0	4.0	
6 Month	23486	3967	16.9	19519	83.1	2.1	0.8	2.0	1.0	4.0	
1 Year	17258	2683	15.5	14575	84.5	2.0	0.8	2.0	1.0	4.0	
2 Year	9794	1441	14.7	8353	85.3	2.0	0.8	2.0	1.0	4.0	
3 Year	5539	825	14.9	4714	85.1	2.0	0.8	2.0	1.0	4.0	
4 Year	3244	464	14.3	2780	85.7	2.1	0.8	2.0	1.0	4.0	
5 Year	1915	275	14.4	1640	85.6	2.1	0.8	2.0	1.0	4.0	

II.C. Post Implant Summary - Functional Capacity

Exhibit 32. NYHA Class

The following figure summarize NYHA Class values your site and STS Intermacs at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Quality of Life****Exhibit 33a. EQ-5D Index**

The following tables summarize EQ-5D Index completion status and values at your site and STS InterMACS at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS						EQ-5D Index				
		Not Done: Other/Unknown		Not Done: Too Sick		Complete						
	N	N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	806	254	31.5	178	22.1	374	46.4	0.6	0.3	0.7	-0.1	1.0
3 Month	614	153	24.9	24	3.9	437	71.2	0.8	0.2	0.8	0.1	1.0
6 Month	528	139	26.3	11	2.1	378	71.6	0.8	0.2	0.8	-0.1	1.0
1 Year	391	127	32.5	3	0.8	261	66.8	0.8	0.2	0.8	-0.0	1.0
2 Year	220	64	29.1	1	0.5	155	70.5	0.8	0.2	0.8	0.2	1.0
3 Year	106	44	41.5	2	1.9	60	56.6	0.8	0.2	0.8	0.3	1.0
4 Year	71	39	54.9	.	.	32	45.1	0.8	0.1	0.8	0.5	1.0
5 Year	31	16	51.6	2	6.5	13	41.9	0.8	0.2	0.8	0.3	1.0


GROUP=STS InterMACS

VISIT	Patients (n)	COMPLETION STATUS						EQ-5D Index					
		Not Done: Other/Unknown		Not Done: Too Sick		Complete							
		N	%	N	%	N	%	Mean	Std	Median	Min	Max	
Pre-Implant	33741	11518	34.1	6511	19.3	15712	46.6	0.6	0.3	0.7	-0.1	1.0	
3 Month	27048	12362	45.7	1032	3.8	13654	50.5	0.8	0.2	0.8	-0.1	1.0	
6 Month	23486	10064	42.9	525	2.2	12897	54.9	0.8	0.2	0.8	-0.1	1.0	
1 Year	17258	7330	42.5	309	1.8	9619	55.7	0.8	0.2	0.8	-0.1	1.0	
2 Year	9794	4339	44.3	155	1.6	5300	54.1	0.8	0.2	0.8	-0.1	1.0	
3 Year	5539	2607	47.1	96	1.7	2836	51.2	0.8	0.2	0.8	-0.0	1.0	
4 Year	3244	1610	49.6	50	1.5	1584	48.8	0.8	0.2	0.8	-0.1	1.0	
5 Year	1915	1022	53.4	37	1.9	856	44.7	0.8	0.2	0.8	-0.0	1.0	

II.C. Post Implant Summary - Quality of Life

Exhibit 33a. EQ-5D Index

The following figure summarize EQ-5D Index values your site and STS Intermacs at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Quality of Life****Exhibit 33b. EQ-5D Visual Analog Scale**

The following tables summarize EQ-5D Visual Analog Scale completion status and values at your site and STS InterMACs at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS						VAS: Own Health State				
		Not Done: Other/Unknown		Not Done: Too Sick		Complete						
	N	N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	806	258	32.0	178	22.1	370	45.9	44.5	27.1	45.0	0.0	100.0
3 Month	614	146	23.8	24	3.9	444	72.3	71.8	22.3	80.0	3.0	100.0
6 Month	528	139	26.3	11	2.1	378	71.6	75.7	18.9	80.0	0.0	100.0
1 Year	391	123	31.5	3	0.8	265	67.8	76.3	18.4	80.0	10.0	100.0
2 Year	220	64	29.1	1	0.5	155	70.5	74.7	19.8	80.0	10.0	100.0
3 Year	106	43	40.6	2	1.9	61	57.5	70.3	20.7	80.0	10.0	100.0
4 Year	71	41	57.7	.	.	30	42.3	72.7	18.9	72.5	20.0	100.0
5 Year	31	16	51.6	2	6.5	13	41.9	72.6	27.6	80.0	0.0	100.0


GROUP=STS InterMACs

VISIT	Patients (n)	COMPLETION STATUS						VAS: Own Health State					
		Not Done: Other/Unknown		Not Done: Too Sick		Complete							
		N	%	N	%	N	%	Mean	Std	Median	Min	Max	
Pre-Implant	33741	11557	34.3	6511	19.3	15673	46.5	45.8	24.3	45.0	0.0	100.0	
3 Month	27048	12452	46.0	1032	3.8	13564	50.1	71.0	19.9	75.0	0.0	100.0	
6 Month	23486	10204	43.4	525	2.2	12757	54.3	73.2	19.4	75.0	0.0	100.0	
1 Year	17258	7490	43.4	309	1.8	9459	54.8	73.6	19.1	78.0	0.0	100.0	
2 Year	9794	4421	45.1	155	1.6	5218	53.3	72.8	19.9	75.0	0.0	100.0	
3 Year	5539	2649	47.8	96	1.7	2794	50.4	72.9	19.4	75.0	0.0	100.0	
4 Year	3244	1610	49.6	50	1.5	1584	48.8	72.9	19.4	75.0	0.0	100.0	
5 Year	1915	1026	53.6	37	1.9	852	44.5	73.7	19.0	80.0	0.0	100.0	

II.C. Post Implant Summary - Quality of Life

Exhibit 33b. EQ-5D Visual Analog Scale

The following figure summarize EQ-5D Visual Analog Scale values your site and STS Intermacs at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.C. Post Implant Summary - Quality of Life****Exhibit 33c. KCCQ-12 - Scored**

The following tables summarize KCCQ-12 - Scored completion status and values at your site and STS InterMACs at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS										
		Not Done: Other/Unknown		Not Done: Too Sick								
		N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	806	334	41.4	153	19.0	319	39.6	35.8	21.5	33.9	0.0	100.0
3 Month	614	224	36.5	20	3.3	370	60.3	62.7	21.7	66.7	0.0	100.0
6 Month	528	193	36.6	10	1.9	325	61.6	67.2	20.9	69.8	4.2	100.0
1 Year	391	149	38.1	3	0.8	239	61.1	66.7	21.4	69.3	10.4	100.0
2 Year	220	77	35.0	.	.	143	65.0	64.8	22.4	68.2	4.9	100.0
3 Year	106	43	40.6	2	1.9	61	57.5	62.0	23.1	66.1	9.4	100.0
4 Year	71	38	53.5	.	.	33	46.5	67.2	21.2	71.9	22.4	100.0
5 Year	31	16	51.6	2	6.5	13	41.9	65.4	28.2	74.0	6.3	100.0


GROUP=STS InterMACs

VISIT	Patients (n)	COMPLETION STATUS						KCCQ-12 Score					
		Not Done: Other/Unknown		Not Done: Too Sick		Complete							
		N	N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	33741	15347	45.5	5257	15.6	13137	38.9	34.2	21.6	30.9	0.0	100.0	
3 Month	27048	14109	52.2	860	3.2	12079	44.7	62.5	20.6	64.6	0.0	100.0	
6 Month	23486	11250	47.9	440	1.9	11796	50.2	66.0	20.5	68.8	0.0	100.0	
1 Year	17258	7985	46.3	267	1.5	9006	52.2	66.3	20.8	68.8	0.0	100.0	
2 Year	9794	4305	44.0	147	1.5	5342	54.5	65.6	21.0	67.7	0.0	100.0	
3 Year	5539	2496	45.1	96	1.7	2947	53.2	65.6	21.2	67.7	0.0	100.0	
4 Year	3244	1495	46.1	52	1.6	1697	52.3	65.7	21.2	68.2	0.0	100.0	
5 Year	1915	957	50.0	39	2.0	919	48.0	66.4	21.2	68.8	6.3	100.0	

II.C. Post Implant Summary - Quality of Life

Exhibit 33c. KCCQ-12 - Scored

The following figure summarize KCCQ-12 - Scored values your site and STS Intermacs at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.




II.E. Post Implant Outcomes

This section provides statistical summaries of outcomes after VAD implant. These depictions include all patients who received a primary device at your institution and compares it with the equivalent group in InterMacS. The p-values are a univariate comparison (log-rank test) of survival at your institution with survival for the entire registry. Univariate comparisons are well known to be limited in value because no adjustment is made for differing patient characteristics in the groups. Nevertheless, these comparisons can provide an initial comparison of unadjusted results. Future version of this report will provide risk adjusted comparisons.

Note: If your site did not report any patients within a specified group, only the overall STS InterMacS data will be displayed.

Exhibit 34a. Post Implant Survival - Device Sequence - STS Intermacs


The following figure compares survival time on specific devices based on device sequence for all of STS Intermacs. Each curve represents survival from the time the device was implanted until death. Patients are censored at time of transplant, explant for any reason, or the device was turned off.



Months after Device Implant	1st Device	2nd Device	3rd Device
1	94.4% (94.2%-94.5%)	88.2% (87.7%-88.7%)	87.1% (85.7%-88.4%)
3	90.1% (89.9%-90.2%)	81.4% (80.7%-82.0%)	79.8% (78.1%-81.3%)
6	86.6% (86.4%-86.8%)	75.9% (75.2%-76.6%)	71.8% (69.9%-73.6%)
9	83.9% (83.7%-84.1%)	71.7% (70.9%-72.5%)	65.2% (63.2%-67.2%)
12	81.4% (81.1%-81.6%)	67.1% (66.2%-67.9%)	62.0% (59.9%-64.0%)
24	71.9% (71.6%-72.2%)	55.2% (54.2%-56.2%)	46.7% (44.4%-49.0%)
36	62.2% (61.8%-62.5%)	46.9% (45.8%-48.0%)	37.4% (34.9%-39.9%)
48	52.9% (52.5%-53.3%)	38.9% (37.7%-40.1%)	30.6% (28.0%-33.3%)
60	44.8% (44.3%-45.3%)	32.6% (31.3%-33.9%)	29.3% (26.6%-32.0%)

Exhibit 34b. Post Implant Survival - Device Sequence - HOSPX-9999

The following figure compares survival time on specific devices based on device sequence for your site. Each curve represents survival from the time the device was implanted until death. Patients are censored at transplant, explant, for any reason, or the device was turned off.




Months after Device Implant	1st Device	2nd Device	3rd Device
1	93.6% (92.7%-94.4%)	83.5% (78.6%-87.4%)	57.1% (36.6%-73.2%)
3	87.9% (86.6%-89.0%)	76.4% (70.9%-81.0%)	57.1% (36.6%-73.2%)
6	84.6% (83.2%-85.9%)	68.6% (62.6%-73.8%)	57.1% (36.6%-73.2%)
9	82.2% (80.8%-83.6%)	68.6% (62.6%-73.8%)	28.6% (13.3%-46.0%)
12	79.9% (78.3%-81.3%)	66.6% (60.5%-72.0%)	28.6% (13.3%-46.0%)
24	71.1% (69.2%-73.0%)	56.8% (49.8%-63.2%)	14.3% (4.4%-29.8%)
36	59.5% (57.0%-61.9%)	53.0% (45.5%-60.0%)	14.3% (4.4%-29.8%)
48	49.7% (46.7%-52.7%)	49.3% (41.4%-56.6%)	
60	42.5% (39.3%-45.8%)	41.0% (31.2%-50.7%)	

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 35. Post Implant Survival - PRIMARY OVERALL




Months after Device Implant	STS Intermacs	HOSPX-9999
1	93.7% (93.6%-93.9%)	92.8% (91.8%-93.6%)
3	89.0% (88.8%-89.1%)	86.5% (85.3%-87.7%)
6	85.3% (85.1%-85.5%)	83.1% (81.7%-84.4%)
9	82.4% (82.2%-82.6%)	80.5% (79.0%-81.9%)
12	79.7% (79.5%-79.9%)	78.1% (76.5%-79.6%)
24	69.7% (69.4%-69.9%)	69.0% (67.0%-70.9%)
36	59.6% (59.2%-59.9%)	56.9% (54.4%-59.2%)
48	50.4% (50.0%-50.8%)	48.5% (45.7%-51.2%)
60	42.4% (41.9%-42.8%)	42.8% (39.9%-45.7%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 36. Post Implant Survival - Primary LVADs




Months after Device Implant	STS Intermacs	HOSPX-9999
1	94.7% (94.5%-94.8%)	94.1% (93.2%-94.9%)
3	90.3% (90.2%-90.5%)	88.0% (86.8%-89.2%)
6	86.8% (86.6%-87.0%)	84.6% (83.2%-85.9%)
9	84.0% (83.8%-84.3%)	82.0% (80.5%-83.4%)
12	81.4% (81.1%-81.6%)	79.5% (77.9%-81.0%)
24	71.1% (70.8%-71.4%)	70.4% (68.4%-72.3%)
36	60.9% (60.5%-61.2%)	58.1% (55.6%-60.5%)
48	51.4% (51.0%-51.9%)	49.4% (46.6%-52.1%)
60	43.2% (42.7%-43.6%)	43.5% (40.5%-46.4%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 37a. Post Implant Survival - Primary LVADs by Era - STS Intermacs




Months after Device Implant	< 2012	2012-2015	2018-2021
1	94.9% (94.6%-95.2%)	95.0% (94.7%-95.2%)	94.4% (94.2%-94.6%)
3	90.0% (89.6%-90.4%)	90.5% (90.2%-90.8%)	90.2% (90.0%-90.5%)
6	85.5% (85.0%-86.0%)	86.8% (86.5%-87.1%)	87.3% (87.0%-87.5%)
9	82.0% (81.4%-82.5%)	83.8% (83.4%-84.1%)	84.9% (84.6%-85.2%)
12	78.7% (78.1%-79.3%)	80.7% (80.3%-81.1%)	82.6% (82.3%-83.0%)
24	66.2% (65.4%-67.0%)	69.7% (69.2%-70.2%)	74.0% (73.5%-74.4%)
36	54.9% (54.0%-55.8%)	59.4% (58.8%-59.9%)	64.5% (64.0%-65.1%)
48	44.6% (43.6%-45.5%)	50.2% (49.6%-50.8%)	55.9% (55.2%-56.6%)
60	37.1% (36.1%-38.0%)	42.1% (41.5%-42.7%)	47.9% (46.9%-48.9%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 37b. Post Implant Survival - Primary LVADs by Era - HOSPX-9999




Months after Device Implant	< 2012	2012-2015	2018-2021
1	94.5% (91.9%-96.3%)	95.6% (94.2%-96.7%)	92.7% (91.2%-94.0%)
3	87.2% (83.6%-90.0%)	91.1% (89.2%-92.7%)	85.9% (83.9%-87.6%)
6	83.2% (79.2%-86.5%)	86.4% (84.1%-88.4%)	83.5% (81.4%-85.4%)
9	79.7% (75.4%-83.4%)	83.9% (81.4%-86.0%)	81.1% (78.9%-83.1%)
12	77.2% (72.6%-81.1%)	81.2% (78.6%-83.5%)	78.9% (76.5%-81.0%)
24	73.0% (67.7%-77.6%)	70.5% (67.3%-73.4%)	69.8% (66.8%-72.6%)
36	58.7% (51.8%-65.0%)	59.5% (55.9%-62.9%)	55.1% (50.6%-59.4%)
48	54.8% (47.2%-61.7%)	52.1% (48.3%-55.8%)	39.9% (34.3%-45.5%)
60	54.8% (47.2%-61.7%)	44.7% (40.6%-48.6%)	34.9% (29.1%-40.8%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 38. Post Implant Survival - Primary BiVADs




Months after Device Implant	STS Intermacs	HOSPX-9999
1	80.1% (79.1%-81.0%)	65.7% (57.0%-73.1%)
3	69.5% (68.4%-70.6%)	57.1% (48.3%-65.0%)
6	62.7% (61.5%-63.9%)	57.1% (48.3%-65.0%)
9	58.1% (56.8%-59.4%)	57.1% (48.3%-65.0%)
12	55.2% (53.8%-56.5%)	57.1% (48.3%-65.0%)
24	48.2% (46.7%-49.6%)	46.6% (36.7%-55.8%)
36	39.8% (38.1%-41.5%)	34.9% (22.9%-47.2%)
48	35.4% (33.6%-37.3%)	34.9% (22.9%-47.2%)
60	31.7% (29.8%-33.6%)	34.9% (22.9%-47.2%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 39. Post Implant Survival - Primary TAHs




Months after Device Implant	STS Intermacs	HOSPX-9999
1	85.0% (83.3%-86.4%)	75.0% (45.6%-90.0%)
3	72.3% (70.3%-74.3%)	50.0% (24.0%-71.4%)
6	61.5% (59.0%-64.0%)	
9	56.5% (53.8%-59.2%)	
12	52.9% (50.0%-55.8%)	
24	40.3% (36.0%-44.5%)	
36	29.3% (23.2%-35.6%)	
48	21.3% (15.1%-28.3%)	
60	10.7% (4.2%-20.5%)	

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 40. Post Implant Survival - Primary LVADs - PULSATILE FLOW




Months after Device Implant	STS Intermacs	HOSPX-9999
1	91.0% (89.8%-92.1%)	100.0% (100.0%-100.0%)
3	81.7% (80.0%-83.2%)	87.5% (69.5%-95.2%)
6	73.7% (71.7%-75.6%)	72.9% (52.4%-85.7%)
9	68.6% (66.4%-70.6%)	72.9% (52.4%-85.7%)
12	62.7% (60.3%-65.0%)	72.9% (52.4%-85.7%)
24	39.7% (36.7%-42.6%)	72.9% (52.4%-85.7%)
36	33.4% (30.3%-36.5%)	
48	27.4% (24.3%-30.6%)	
60	24.4% (21.4%-27.6%)	

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 41. Post Implant Survival - Primary LVADs - CONTINUOUS FLOW




Months after Device Implant	STS Intermacs	HOSPX-9999
1	94.7% (94.6%-94.9%)	94.0% (93.1%-94.8%)
3	90.5% (90.3%-90.7%)	88.0% (86.8%-89.2%)
6	87.1% (86.9%-87.3%)	84.7% (83.3%-86.0%)
9	84.3% (84.1%-84.5%)	82.1% (80.6%-83.5%)
12	81.7% (81.4%-81.9%)	79.6% (78.0%-81.1%)
24	71.6% (71.3%-71.9%)	70.4% (68.5%-72.3%)
36	61.3% (60.9%-61.6%)	58.4% (55.9%-60.8%)
48	51.8% (51.4%-52.2%)	49.6% (46.8%-52.4%)
60	43.4% (43.0%-43.9%)	43.7% (40.7%-46.7%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 42. Post Implant Survival - Listed for Transplant - CONTINUOUS FLOW




Months after Device Implant	STS Intermacs	HOSPX-9999
1	95.4% (95.1%-95.6%)	95.3% (93.0%-96.8%)
3	92.3% (92.0%-92.6%)	90.2% (87.2%-92.6%)
6	89.7% (89.3%-90.1%)	86.5% (83.0%-89.4%)
9	87.3% (86.9%-87.8%)	83.2% (79.2%-86.4%)
12	85.1% (84.6%-85.6%)	81.7% (77.6%-85.2%)
24	76.8% (76.2%-77.5%)	76.4% (71.4%-80.7%)
36	67.8% (67.0%-68.7%)	64.0% (57.2%-70.0%)
48	58.0% (57.0%-59.1%)	52.6% (44.2%-60.3%)
60	49.3% (48.0%-50.5%)	47.3% (38.3%-55.8%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 43. Post Implant Survival - Bridge to Candidacy - CONTINUOUS FLOW




Months after Device Implant	STS Intermacs	HOSPX-9999
1	95.1% (94.9%-95.3%)	92.9% (90.9%-94.5%)
3	90.9% (90.6%-91.2%)	88.3% (85.8%-90.4%)
6	87.7% (87.3%-88.0%)	85.7% (82.9%-88.0%)
9	84.7% (84.3%-85.1%)	83.7% (80.8%-86.2%)
12	82.3% (81.8%-82.7%)	81.0% (77.8%-83.7%)
24	72.8% (72.3%-73.4%)	69.7% (65.4%-73.6%)
36	62.8% (62.1%-63.5%)	64.4% (59.6%-68.7%)
48	53.9% (53.1%-54.7%)	55.0% (49.3%-60.3%)
60	45.8% (44.9%-46.7%)	55.0% (49.3%-60.3%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 44. Post Implant Survival - Destination Therapy - CONTINUOUS FLOW




Months after Device Implant	STS Intermacs	HOSPX-9999
1	93.2% (93.0%-93.4%)	93.1% (91.9%-94.2%)
3	87.9% (87.7%-88.2%)	86.2% (84.5%-87.7%)
6	83.9% (83.6%-84.2%)	82.9% (81.0%-84.6%)
9	81.0% (80.7%-81.3%)	80.3% (78.3%-82.1%)
12	78.1% (77.8%-78.5%)	77.8% (75.7%-79.8%)
24	67.5% (67.1%-67.9%)	68.5% (65.9%-70.8%)
36	56.9% (56.4%-57.4%)	54.1% (50.9%-57.1%)
48	47.7% (47.1%-48.2%)	46.5% (43.0%-49.9%)
60	39.7% (39.1%-40.3%)	39.1% (35.5%-42.7%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 45a. Post Implant Survival: Patient Profile 1 - Critical Cardiogenic Shock




Months after Device Implant	STS Intermacs	HOSPX-9999
1	88.6% (88.2%-89.0%)	83.7% (80.1%-86.8%)
3	81.3% (80.8%-81.8%)	73.1% (68.9%-76.9%)
6	76.8% (76.3%-77.4%)	70.5% (66.1%-74.4%)
9	73.6% (73.0%-74.2%)	69.5% (65.1%-73.5%)
12	70.9% (70.3%-71.5%)	65.2% (60.6%-69.5%)
24	62.0% (61.3%-62.8%)	57.6% (52.3%-62.5%)
36	53.5% (52.6%-54.3%)	48.9% (42.5%-55.1%)
48	45.5% (44.5%-46.5%)	33.8% (26.3%-41.6%)
60	40.0% (38.9%-41.0%)	29.6% (22.0%-37.5%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 45b. Post Implant Survival: Patient Profile 2 - Progressive Decline




Months after Device Implant	STS Intermacs	HOSPX-9999
1	93.9% (93.6%-94.1%)	92.4% (90.5%-93.9%)
3	88.9% (88.6%-89.2%)	86.7% (84.3%-88.7%)
6	84.8% (84.5%-85.1%)	82.7% (80.2%-85.0%)
9	81.9% (81.5%-82.3%)	78.9% (76.0%-81.4%)
12	79.3% (78.9%-79.7%)	77.3% (74.4%-79.9%)
24	68.7% (68.2%-69.2%)	65.2% (61.5%-68.7%)
36	58.4% (57.8%-59.0%)	51.3% (46.9%-55.6%)
48	49.5% (48.8%-50.1%)	44.0% (39.1%-48.8%)
60	41.6% (40.8%-42.4%)	37.6% (32.5%-42.6%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 45c. Post Implant Survival: Patient Profile 3 - Stable but Inotrope Dependent




Months after Device Implant	STS Intermacs	HOSPX-9999
1	95.9% (95.7%-96.1%)	95.6% (94.4%-96.6%)
3	92.2% (92.0%-92.5%)	90.6% (88.9%-92.0%)
6	89.3% (89.0%-89.6%)	87.0% (85.0%-88.7%)
9	86.6% (86.3%-86.9%)	84.6% (82.5%-86.4%)
12	83.8% (83.4%-84.1%)	82.7% (80.5%-84.7%)
24	73.9% (73.4%-74.4%)	74.4% (71.6%-76.9%)
36	63.1% (62.5%-63.8%)	61.3% (57.6%-64.8%)
48	53.8% (53.1%-54.5%)	53.7% (49.6%-57.6%)
60	45.1% (44.3%-45.9%)	47.8% (43.4%-52.1%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 45d. Post Implant Survival: Patient Profile 4+ Resting Symptoms and Less Sick



Intermacs

Months after Device Implant	STS Intermacs	HOSPX-9999
1	95.6% (95.3%-95.9%)	95.2% (91.5%-97.3%)
3	92.2% (91.8%-92.6%)	88.5% (83.7%-92.0%)
6	88.7% (88.2%-89.1%)	86.9% (81.8%-90.6%)
9	86.0% (85.5%-86.5%)	85.0% (79.7%-89.0%)
12	83.4% (82.8%-83.9%)	80.6% (74.5%-85.3%)
24	72.8% (72.0%-73.5%)	75.4% (68.7%-80.9%)
36	62.7% (61.8%-63.6%)	67.4% (59.9%-73.9%)
48	51.9% (50.9%-53.0%)	59.0% (50.2%-66.7%)
60	42.5% (41.3%-43.6%)	54.8% (45.7%-63.0%)

Exhibit 46a. Competing Outcomes - Primary LVADs - CONTINUOUS FLOW - STS Intermacs


[illegible]

Exhibit 46b. Competing Outcomes - Primary LVADs - CONTINUOUS FLOW - HOSPX-9999



[illegible]

Exhibit 47a. Competing Outcomes - Primary TAHs - STS Intermacs

[illegible]

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 47b. Competing Outcomes - Primary TAHs - HOSPX-9999

Not enough patients or events to produce exhibit

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients***COVERAGE: June 23, 2006 - June 30, 2021******SITE: HOSPX - DEMO SITE REPORT******IV. Zone Conditions: Hemolysis, Hypertension, and Right Heart Failure***

The following Exhibits consist of data collected regarding the three “Zone Conditions”: Hemolysis, Hypertension, and Right Heart Failure. These zones were added to the STS InterMACS released in June of 2014. The zone sections, including data fields and flag calculations, were added to the Web Based Data Entry (WBDE) system. In the WBDE, the flags are calculated on any applicable form that is updated by a user after the release date, and the flags are displayed in the WBDE (on the Patient Summary). The report exhibits on the following pages provide useful, clinical analysis of the flags by adding comparison to the STS InterMACS Aggregate Group, and include some further division into relevant categories, such as classification of severity, and timing.

Note: Further information on the calculation and processing of the Zone Conditions can be found on the [InterMACS.org](https://www.stsintermacs.org) website, in the Reports FAQ section. For any queries about the zone conditions or the exhibits, please don’t hesitate to contact the InterMACS Data Warehouse and Analytics Center.

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 48a: Hemolysis Evaluation Condition Coverage at Follow-up

The table below consists of data that was collected in the Hemolysis Zone for each Follow-Up interval. Patients that were implanted with a Primary Device on or after June 2, 2014 are analyzed in this exhibit. In the 'Unable to Evaluate' column, the condition could not be evaluated due to missing variables.

GROUP=HOSPX-9999

Follow-up Visit	Hemolysis Evaluation				
	All	Unable to Evaluate		Condition Evaluated	
		N	%	N	%
3 Month	387	.	.	387	100.00
6 Month	337	2	0.59	335	99.41
1 Year	248	1	0.40	247	99.60
2 Year	131	2	1.53	129	98.47

GROUP=STS Intermacs

Follow-up Visit	Hemolysis Evaluation				
	All	Unable to Evaluate		Condition Evaluated	
		N	%	N	%
3 Month	17132	868	5.07	16264	94.93
6 Month	14969	762	5.09	14207	94.91
1 Year	11008	450	4.09	10558	95.91
2 Year	5969	237	3.97	5732	96.03

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

IV. Zone Conditions: Hemolysis

Exhibit 48b: Hemolysis Major and Minor Condition Coverage at Follow-up

The table below consists of patients who had Major or Minor Hemolysis Conditions for each Follow-Up interval. Patients that were implanted with a Primary Device on or after June 2, 2014 are analyzed in this exhibit.

GROUP=HOSPX-9999

Follow-up Visit	Hemolysis Condition						
	All	Major		Minor		No	
	N	N	%	N	%	N	%
3 Month	387	17	4.39	60	15.50	310	80.10
6 Month	335	9	2.69	39	11.64	287	85.67
1 Year	247	9	3.64	29	11.74	209	84.62
2 Year	129	5	3.88	21	16.28	103	79.84
3 Year	49	2	4.08	7	14.29	40	81.63
4 Year	36	1	2.78	9	25.00	26	72.22
5 Year	14	2	14.29	3	21.43	9	64.29

GROUP=STS Intermacs

Follow-up Visit	Hemolysis Condition						
	All	Major		Minor		No	
	N	N	%	N	%	N	%
3 Month	16264	610	3.75	2729	16.78	12925	79.47
6 Month	14207	392	2.76	2260	15.91	11555	81.33
1 Year	10558	386	3.66	1892	17.92	8280	78.42
2 Year	5732	204	3.56	968	16.89	4560	79.55
3 Year	2928	121	4.13	530	18.10	2277	77.77
4 Year	1499	70	4.67	268	17.88	1161	77.45
5 Year	740	30	4.05	135	18.24	575	77.70

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 48c: Hypertension Evaluation Condition Coverage at Follow-up

The table below consists of data that was collected in the Hypertension Zone for each Follow-Up interval. Patients that were implanted with a Primary Device on or after June 2, 2014 are analyzed in this exhibit. In the 'Unable to Evaluate' column, the condition could not be evaluated due to missing variables.

GROUP=HOSPX-9999

Follow-up Visit	Hypertension Evaluation				
	All	Unable to Evaluate		Condition Evaluated	
		N	%	N	%
3 Month	387	168	43.41	219	56.59
6 Month	337	139	41.25	198	58.75
1 Year	248	120	48.39	128	51.61
2 Year	131	80	61.07	51	38.93

GROUP=STS Intermacs

Follow-up Visit	Hypertension Evaluation				
	All	Unable to Evaluate		Condition Evaluated	
		N	%	N	%
3 Month	17132	4277	24.96	12855	75.04
6 Month	14969	3649	24.38	11320	75.62
1 Year	11008	2703	24.55	8305	75.45
2 Year	5969	1524	25.53	4445	74.47

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients**COVERAGE: June 23, 2006 - June 30, 2021****SITE: HOSPX - DEMO SITE REPORT*****Exhibit 48d: Hypertension No or Yes Condition Coverage at Follow-up***

The table below consists of patients who did or did not have Hypertension Conditions for each Follow-Up interval. Patients that were implanted with a Primary Device on or after June 2, 2014 are analyzed in this exhibit.

GROUP=HOSPX-9999

Follow-up Visit	All	Hypertension Condition			
		HTN		No HTN	
		N	%	N	%
3 Month	219	8	3.65	211	96.35
6 Month	198	11	5.56	187	94.44
1 Year	128	8	6.25	120	93.75
2 Year	51	11	21.57	40	78.43
3 Year	21	.	.	21	100.00
4 Year	18	5	27.78	13	72.22
5 Year	3	1	33.33	2	66.67

GROUP=STS InterMACs

Follow-up Visit	All	Hypertension Condition			
		HTN		No HTN	
		N	%	N	%
3 Month	12855	624	4.85	12231	95.15
6 Month	11320	596	5.27	10724	94.73
1 Year	8305	448	5.39	7857	94.61
2 Year	4445	268	6.03	4177	93.97
3 Year	2258	110	4.87	2148	95.13
4 Year	1163	72	6.19	1091	93.81
5 Year	538	26	4.83	512	95.17

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

IV. Zone Conditions: Right Heart Failure

Exhibit 48e: Right Heart Failure Evaluation Condition Coverage at Follow-up

The table below consists of data that was collected in the Right Heart Failure Zone for each Follow-Up interval. Patients that were implanted with a Primary Device on or after June 2, 2014 are analyzed in this exhibit. In the 'Unable to Evaluate' column, the condition could not be evaluated due to missing variables.

GROUP=HOSPX-9999

Follow-up Visit	All	RHF Evaluation			
		Unable to Evaluate		Condition Evaluated	
		N	%	N	%
3 Month	387	15	3.88	372	96.12
6 Month	337	9	2.67	328	97.33
1 Year	248	9	3.63	239	96.37
2 Year	131	4	3.05	127	96.95

GROUP=STS Intermacs

Follow-up Visit	All	RHF Evaluation			
		Unable to Evaluate		Condition Evaluated	
		N	%	N	%
3 Month	17132	713	4.16	16419	95.84
6 Month	14969	513	3.43	14456	96.57
1 Year	11008	346	3.14	10662	96.86
2 Year	5969	137	2.30	5832	97.70

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 48f: Right Heart Failure Evaluation Condition Coverage at Follow-up

The table below consists of patients who Right Heart Failure for each Follow-Up interval, including analysis of severity. Patients that were implanted with a Primary Device on or after June 2, 2014 are analyzed in this exhibit. For full details on how each severity level is calculated, please check the Reports FAQ section on the Intermacs.org website.

GROUP=HOSPX-9999

Follow-up Visit		RHF Condition									
		All		1. No RHF		3. RHF (Mild)		4. RHF (Inotropic Support)		5. RHF (RVAD Support)	
		N	%	N	%	N	%	N	%	N	%
3 Month	372	352	94.62	9	2.42	10	2.69	1	0.27		
6 Month	328	317	96.65	7	2.13	3	0.91	1	0.30		
1 Year	239	228	95.40	10	4.18	1	0.42				
2 Year	127	126	99.21	1	0.79						
3 Year	49	48	97.96	1	2.04						
4 Year	36	36	100.00								
5 Year	14	13	92.86			1	7.14				

GROUP=STS Intermacs

Follow-up Visit	All	RHF Condition							
		1. No RHF		3. RHF (Mild)		4. RHF (Inotropic Support)		5. RHF (RVAD Support)	
		N	%	N	%	N	%	N	%
3 Month	16419	14573	88.76	840	5.12	967	5.89	39	0.24
6 Month	14456	13203	91.33	694	4.80	545	3.77	14	0.10
1 Year	10662	9666	90.66	607	5.69	385	3.61	4	0.04
2 Year	5832	5349	91.72	288	4.94	189	3.24	6	0.10
3 Year	2988	2756	92.24	137	4.59	93	3.11	2	0.07
4 Year	1542	1403	90.99	84	5.45	54	3.50	1	0.06
5 Year	748	681	91.04	34	4.55	33	4.41		

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients**COVERAGE: June 23, 2006 - June 30, 2021****SITE: HOSPX - DEMO SITE REPORT****Exhibit 49: Patients Implanted at your Center but Excluded from the Cumulative - All Patient Report**

Excluded Patient ID	Exclusion Reason	Implant Year
452	Retrospective Patient	2006
631	Pediatric Patient (Age<19)	2007
1060	Patient Implant Date Outside of Report Coverage	2006
4756	Pediatric Patient (Age<19)	2011
5048	Pediatric Patient (Age<19)	2011
5561	Retrospective Patient	2010
5590	Retrospective Patient	2010
5591	Retrospective Patient	2010
5593	Retrospective Patient	2010
7012	Pediatric Patient (Age<19)	2012
107122	Retrospective Patient	2015
116990	Retrospective Patient	2018
125366	Implant, Pre-Implant, or Patient form not validated	2020
125722	Implant, Pre-Implant, or Patient form not validated	2020
126037	Implant, Pre-Implant, or Patient form not validated	2020
126223	Implant, Pre-Implant, or Patient form not validated	2020
126245	Implant, Pre-Implant, or Patient form not validated	2020
126375	Implant, Pre-Implant, or Patient form not validated	2020
126411	Implant, Pre-Implant, or Patient form not validated	2020
126738	Implant, Pre-Implant, or Patient form not validated	2021
126823	Implant, Pre-Implant, or Patient form not validated	2021
126928	Implant, Pre-Implant, or Patient form not validated	2021
127069	Implant, Pre-Implant, or Patient form not validated	2021
127251	Implant, Pre-Implant, or Patient form not validated	2021
127334	Implant, Pre-Implant, or Patient form not validated	2021
127727	Implant, Pre-Implant, or Patient form not validated	2021
127743	Implant, Pre-Implant, or Patient form not validated	2021
127744	Implant, Pre-Implant, or Patient form not validated	2021
127829	Implant, Pre-Implant, or Patient form not validated	2021
127830	Implant, Pre-Implant, or Patient form not validated	2021
127984	Implant, Pre-Implant, or Patient form not validated	2021
128045	Implant, Pre-Implant, or Patient form not validated	2021

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Cumulative - All Patients

COVERAGE: June 23, 2006 - June 30, 2021


SITE: HOSPX - DEMO SITE REPORT

III. Registry Compliance

Exhibit 50. Compliance

Site compliance is determined by the percentage of all follow-up forms that are due during this reporting period that have been completed. **This calculation has been updated to include ALL follow-up forms expected for ALL patients and ALL devices.** Only active sites that have at least 10 follow-up forms due are included in this figure (n = 172 sites). This exhibit is the same in both cumulative and recent report. It is based on all follow-up forms.

STS InterMACS has defined required compliance as 90%. If your hospital is below 90%, please examine your patient follow-up table that is contained in the STS InterMACS Data Quality Quarterly Report. This table will identify the exact patients who have a 'past due' follow-up form.



BiVAD: BiVentricular Assist Device
BMI: Body Mass Index
BP: Blood Pressure
BSA: Body Surface Area
BTC: Bridge to Candidacy
BUN: Blood Urea Nitrogen
CMS: Centers for Medicare and Medicaid
COPD: Chronic Obstructive Pulmonary Disease
CNS: Central Nervous System
CRP: C - Reactive Protein
CVA: Cerebrovascular Accident
DCC: Data Coordinating Center
DT: Destination Therapy
ECMO: Extracorporeal-membrane Oxygenation
EQ-5D: Euro Quality of Life
FDA: Federal Drug Administration
HF: Heart Failure
IABP: Intra-Aortic Balloon Pump
IgG: Immunoglobulin G
INR: International Normalized Ratio
Intermacs: Interagency Registry for Mechanically Assisted Circulatory Support
LVAD: Left Ventricular Assist Device
LVEF: Left Ventricular Ejection Fraction
LVEDD: Left Ventricular End Diastolic Dysfunction
LVSF: Left Ventricular Shortening Fraction
MCSD: Mechanically Circulatory Support Device
NHLBI: National Heart Lung and Blood Institute
NT pro brain natriuretic peptide: N-Terminal pro brain Natriuretic peptide
NYHA: New York Heart Association
OR: Operating Room
Regurg: Regurgitation
RVAD: Right Ventricular Assist Device
RVEF: Right Ventricular Ejection Fraction
SAE: Serious Adverse Event
SGOT-AST: Serum Glutamic Oxaloacetic Transaminase
SGPT-ALT: Serum Glutamic Pyruvic Transaminase
STS: Society of Thoracic Surgeons
TAH: Total Artificial Heart
TIA: Transient Ischemic Attack
VAD: Ventricular Assist Device
VAS: Visual Analog Scale